Key Points {#FPar1}
==========

The use of dopamine agonists could contribute to the development of impulse control disorders (ICDs).We need to consider ICDs as multifactorial disorders, involving drug-, patient-, and disease-related factors.

Introduction {#Sec1}
============

Dopamine and Dopaminergic Pathways in the Central Nervous System {#Sec2}
----------------------------------------------------------------

Dopamine is a neurotransmitter that is particularly important as it is involved in both everyday brain functioning (such as the control of motor function, motivation, and reinforcement learning) and in several common disorders of brain functioning, notably Parkinson's disease (PD), drug dependence, and certain endocrine disorders \[[@CR1]\]. Three main dopaminergic pathways are described in the central nervous system (CNS): (i) the nigrostriatal pathway consisting of cell bodies in the substantia nigra whose axons terminate in the corpus striatum; (ii) the mesocorticolimbic pathway (also known as the reward system), whose cell bodies are situated in the ventral tegmental area and whose axons project to parts of the limbic system, in particular the nucleus accumbens (NAcc) and the amygdaloid nucleus, and to the frontal cortex; and (iii) the tuberoinfundibular pathway, whose cell bodies are found in the ventral hypothalamus and project to the median eminence and pituitary gland \[[@CR1]\]. The first pathway is particularly involved in motor function, while the second pathway is especially implicated in reward- and aversion-related cognition as well as executive functions. The third pathway influences the secretion of certain hormones, including prolactin. The impairment of these different pathways leads to a variety of disorders, ranging from important motor deficits (as is the case in PD) to the compulsive repetition of rewarding behavior (as is the case in addictive disorders and ICDs).

Dopamine Agonists {#Sec3}
-----------------

Dopamine agonists (DAAs) represent a pharmacological class of drugs that act on the nervous system. The following molecules are all DAAs: bromocriptine, pergolide, piribedil, lisuride, cabergoline, pramipexole, ropinirole, rotigotine, and apomorphine. The main indication of this class of drug is PD. Bromocriptine, pergolide, piribedil, and cabergoline exhibit a slight selectivity for dopamine D~2/3~ over D~1~ receptors. Lisuride acts specifically on D~2~ receptors. The use of bromocriptine, pergolide, lisuride, and cabergoline, which are all ergot derivatives, is currently limited mainly due to their adverse effects. The aforementioned drugs have in fact been supplanted by pramipexole and ropinirole, which are D~2/3~ selective and thus better tolerated \[[@CR1]\]. These two drugs have a highly specific affinity to cerebral D~3~ receptors, which are known to be localized to the mesolimbic system \[[@CR2]\]. Rotigotine is a newer DAA, delivered via transdermal patch, which is highly selective to D~3~ receptors as compared to D~2~ receptors. Apomorphine, which has approximately equal affinities for D~2~ and D~3~ \[[@CR3]\], is only active when administered via injection and has a short onset time and duration.

Parkinson's Disease, But Also Restless Legs Syndrome and Prolactinoma... {#Sec4}
------------------------------------------------------------------------

DAAs are mainly indicated to treat PD, although they are also used to relieve symptoms of restless legs syndrome (RLS) and prolactinoma or lactation inhibition. Others diseases may be anecdotally targeted by the prescription of DAAs, including fibromyalgia \[[@CR4]\] and tetrahydrobiopterin deficiency \[[@CR5]\], but use for these diseases falls outside of the approved recommendations.

Impulse Control Disorders (ICDs) Associated with Dopamine Agonists {#Sec5}
------------------------------------------------------------------

When treating CNS disorders, it is often a desire to target a certain type of receptor; activating or inhibiting it in only a specific neuronal pathway. However, drug action is rarely limited to one region of the brain and a drug tends to impact a given receptor type throughout the brain \[[@CR1]\]. The first cases of iatrogenic impulsive behaviors were reported in the early 2000s after DAAs received marketing authorization and began to be widely prescribed for PD \[[@CR6], [@CR7]\]. These first cases were considered to be iatrogenic based on chronological and pharmacological arguments: (i) they appeared after the onset of PD and dopamine replacement therapy (DRT) initiation and disappeared after discontinuing DRT; and (ii) DRT acted on dopamine receptors in both the nigrostriatal pathway and the reward pathway, which plays a role in addictive behavior. Several reviews have compiled published case reports or case series \[[@CR8], [@CR9]\] on this topic. Reported impulsive behaviors were pathological gambling, hypersexuality, compulsive shopping, binge eating, obsessive hobbying, punding, and compulsive medication use. The authors have rigorously examined the link between DRT and iatrogenic impulsive behaviors while considering a large range of disorders under a single umbrella term: impulse control disorders (ICDs) \[[@CR10], [@CR11]\]. ICDs are a heterogeneous group of diseases that are now included in the extended "Disruptive, Impulse Control, and Conduct Disorders" chapter in the *Diagnostic and Statistical Manuel of Mental Disorders, Fifth Edition* (DSM-5) \[[@CR12]\]. ICDs involve dysfunctions in both emotional and behavioral regulation. A shared key symptom of all ICDs is the failure to resist an impulse or temptation to perform an act that is harmful to a person or to others \[[@CR13]\]. Individuals experience an increased sense of tension prior to an act and pleasure, gratification, or the release of tension at the time of committing the act. Some disorders that are classified in other nosographic categories (binge eating disorder in "Feeding and Eating Disorders" or gambling disorder in "Substance-Related and Addictive Disorders") are considered in the literature in this field as ICDs due to their clinical proximity or evolutions in classifications. Similar adverse drug reactions have also been reported in RLS \[[@CR14]--[@CR23]\] and prolactinoma patients \[[@CR24], [@CR25]\], thus implying that nigrostriatal denervation is not a prerequisite for the development of ICD. However, only a minority of individuals with from PD, RLS, or prolactinoma develop ICDs. This is in contrast to the high frequency of the other adverse effects (i.e., nausea, low blood pressure, or nightmares), which are directly linked to the central or peripheral action of DAAs. Concluding that medication is the only factor involved in the onset of ICDs would be simplistic and dangerous. Many other potential risk factors should be considered, including individual predisposition and/or disease-related factors.

Lack of Evidence {#Sec6}
----------------

A substantial amount of literature is consecrated to the examination of the links between the use of DAAs in PD and the development of ICDs \[[@CR2], [@CR11], [@CR13], [@CR26]--[@CR63]\], and this topic continues to be a very active field of research. In most cases, emphasis is placed on iatrogenic factors. Furthermore, the same association in RLS or prolactinoma is rarely addressed, and, to the best of our knowledge, there is no review available that takes into account the three diseases for which DAAs are prescribed. To fill this void, we undertook a comprehensive review of ICDs simultaneous to DAA use, integrating iatrogenic factors, predisposing factors, and disease-related factors. We decided to focus only on original articles based on a control study design. Finally, recommendations to manage ICDs are briefly provided.

Materials and Methods {#Sec7}
=====================

A systematic review of available literature was conducted to identify all relevant publications pertaining to the links between the use of DAAs and ICDs. For this review, we complied with the Preferred Reporting Items for systematic reviews and Meta-Analyses (PRISMA) \[[@CR64]\].

Search Resources {#Sec8}
----------------

A search of two electronic databases was completed from inception to July 2017: PubMed and ScienceDirect. The search terms were medical subject headings (MeSH) terms including "Dopamine Agonists" AND "Disruptive, Impulse Control, and Conduct Disorders" found in the title, abstract, or keywords. Duplicates were eliminated. Additional records were included after manual search. The search strategy is summarized in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Flow chart of the search

Eligibility Criteria {#Sec9}
--------------------

Articles had to fulfill the following criteria to be included:The target problem was an impulse control disorder;The medication was a dopaminergic drug; andThe article was an original article.

Article Selection {#Sec10}
-----------------

Firstly, articles were selected based on their titles and abstracts. Secondly, the full text of all of the included articles was read. Two of the authors (MGB and GCB) performed this work independently using the same bibliographic search. In the event of disagreement, the relevant articles were discussed.

Data Extraction {#Sec11}
---------------

Clinical and pharmacological data were extracted from the articles (by MGB, YD, JL, MR, ET, NZ, and GCB). Factors taken into account included the sample size of the studies, the type of participants, the characteristics of the disease, the characteristics of the drug, the study design, and the objectives. The main results are presented in tables that summarize the prevalence data, the iatrogenic factors, the patient-related factors and the disease-related factors (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"} in Appendix).

Results {#Sec12}
=======

Ninety articles met the criteria for inclusion. DAAs were used in PD, RLS, or prolactinoma.

Prevalence {#Sec13}
----------

The results of the prevalence survey are presented in Table [1](#Tab1){ref-type="table"} in Appendix.

In PD patients, the prevalence of ICDs in general ranged from 2.6% \[[@CR65]\] to 34.8% \[[@CR66]\], reaching higher rates in specific populations: 39.1% in patients only treated using DAAs with a predefined minimum exposure to DAAs after study enrollment of at least 50 levodopa ([l]{.smallcaps}-dopa) equivalent daily dose (DAA-LEDD, calculated using the standard conversion factors described by Tomlinson and colleagues \[[@CR67]\]) of DAA for at least 3 consecutive months \[[@CR68]\] or 58.3% in early-onset PD (EOPD) patients \[[@CR69]\]. No ICD stood out more than another, and authors reported discordant results concerning the frequency of each ICD.

In RLS patients, reported prevalences were lower, between 7.1% \[[@CR70]\] and 11.4% \[[@CR71]\]. Surprisingly, Bayard et al. \[[@CR72]\] reported rates that were even lower for patients taking DAAs (2%) than for drug-free patients (2.5%), although DAA doses were three to five times lower in that study's RLS population than in other RLS populations.

We found only two studies about prolactinoma. ICDs were observed in two patients out of 20 in one study \[[@CR73]\], and concerned a quarter of the sample in another \[[@CR74]\].

Drug-Related Factors {#Sec14}
--------------------

The results regarding drug-related factors are presented in Table [2](#Tab2){ref-type="table"} in Appendix.

Exposure to DRT was found to be a risk factor in the emergence of an adverse drug event such as ICD, and patients with ICDs were shown to take a significantly higher LEDD \[[@CR75]--[@CR83]\]. A study assessing PD patients treated with low dosages of DRT did not find any significant association between drug-related factors and ICDs after multivariate analysis \[[@CR86]\].

### Type of Dopamine Agonist (DAA) {#Sec15}

Both DAA and [l]{.smallcaps}-dopa use was implicated in the development of ICDs in PD patients, although the odds ratio (OR) was nearly twice as high for DAAs \[[@CR84]\]. According to numerous studies, DAA use is an independent predictor for developing an ICD in PD patients \[[@CR75], [@CR78], [@CR83]--[@CR96]\]. The six US Food and Drug Administration (FDA)-approved DAAs (pramipexole, ropinirole, cabergoline, bromocriptine, rotigotine, and apomorphine) had a strong signal, the strongest being pramipexole and ropinirole, which both have a preferential affinity for D~3~ receptors \[[@CR91]\]. Several studies highlighted a potentially causal role of pramipexole \[[@CR85], [@CR90]\]. However, other studies did not conclude that there were any significant associations with respect to a specific DAA \[[@CR68], [@CR86], [@CR97]\].

### Dose of DAA {#Sec16}

For many authors, exposure to a higher daily dose of DAA \[[@CR70], [@CR77], [@CR81], [@CR86], [@CR90], [@CR93], [@CR98], [@CR99]\] and a higher peak DAA dose \[[@CR68]\] were significantly associated with the development of ICDs. Only a few studies did not find any association with dosage \[[@CR80], [@CR100], [@CR101]\]. Two studies assessed the dose--response relationship. Lee et al. \[[@CR102]\] reported a DAA dose--response relationship with compulsive shopping, gambling, and hypersexuality, and Perez-Lloret et al. \[[@CR103]\] noted a non-linear dose--response relationship between DAAs and the frequency of ICD symptoms. Finally, a longitudinal study showed a recovery from compulsive behaviors after reducing the dosage of DAAs in 16 patients out of 22 \[[@CR104]\].

### Duration of DAA Treatment {#Sec17}

It is difficult to draw conclusions on the link between DAA treatment duration and ICDs. For some authors, DAA treatment duration seemed to have an influence, with a longer duration being associated with the development of ICDs \[[@CR105], [@CR106]\], while for other authors DAA treatment duration was non-significant \[[@CR68]\]. In long-term studies of rotigotine transdermal patches, the incidence of ICDs was relatively low during the first 30 months of exposure and higher over the next 30 months \[[@CR107]\].

### DAA Formulation {#Sec18}

Most studies did not indicate the drug formulations employed. Yet, some recent publications have discussed the relevance of extended formulations. Todorova et al. \[[@CR108]\] thus demonstrated that infusion therapies (apomorphine infusion and intrajejunal [l]{.smallcaps}-dopa infusion) were associated with the resolution or attenuation of pre-existing ICDs. ICDs could, however, develop after apomorphine infusion initiation, but the rate remained lower than that reported for oral short-acting DAAs \[[@CR108]\]. Transdermal patches of rotigotine provide continuous drug delivery with a stable plasma concentration over 24 h. It is suggested that extended formulations limit ICD development compared with immediate-release (IR) formulations. Nevertheless, ICDs were reported as an adverse drug reaction in rotigotine long-term treatment \[[@CR107]\].

### Biological Aspects {#Sec19}

From a neurobiological point of view, DAA use implies a modification of the neuronal signaling of reward expectation (mesolimbic dopaminergic hyperactivation), resulting in a sensitization towards ICDs \[[@CR109]\]. DAAs may abate negative reinforcement in feedback-based learning \[[@CR110]\]. A case-control study showed a significant DAA-induced reduction of neuronal activity in brain areas that are implicated in impulse control and response inhibition (lateral orbitofrontal cortex, rostral cingulated zone, amygdala, and external pallidum) in PD patients with DAA-induced pathological gambling compared with that of PD controls \[[@CR111]\]. Furthermore, when using different forms of decision-making tasks, including delay-discounting tasks, DAA use was associated with greater choice impulsivity \[[@CR79], [@CR112]\], shorter reaction time \[[@CR112], [@CR113]\], and increased risk-taking \[[@CR114], [@CR115]\] in PD patients with ICDs compared with PD controls. Exogenous dopamine influences impulsive decision-making, which may precipitate the development of ICDs \[[@CR79]\]. In PD patients with hypersexuality, DAA use results in an increased sexual desire after exposure to sexual content compared with non-medicated PD patients \[[@CR89]\].

In RLS patients, the underlying neurobiology remains less clear. Bayard et al. \[[@CR72]\] observed reduced decision-making capacity where outcome probabilities were unknown, although no difference was observed between drug-free and DAA-treated patients \[[@CR72]\]. It is important to note that DAA doses were three to five times lower in this study population than in other RLS populations.

Patient-Related Factors {#Sec20}
-----------------------

The results relating to patient-related factors are presented in Table [3](#Tab3){ref-type="table"} in Appendix.

### Sociodemographic Characteristics {#Sec21}

#### Gender {#Sec22}

Male gender was commonly found as an independent predictor for developing ICDs \[[@CR66], [@CR77], [@CR78], [@CR97], [@CR105], [@CR116], [@CR117]\] as well as for pathological gambling or hypersexuality \[[@CR102]\] in PD patients and in prolactinoma patients \[[@CR74]\]. In contrast, female gender was associated with the resolution of ICDs in PD patients during follow-up \[[@CR100]\]. Female gender was found to be more frequent in RLS patients with ICDs \[[@CR70]\].

#### Age {#Sec23}

A younger age \[[@CR77], [@CR80], [@CR82], [@CR84], [@CR87], [@CR92], [@CR96], [@CR97], [@CR117]--[@CR119]\] and an age under 65 years \[[@CR66]\] or 68 years \[[@CR103]\] were also commonly found to be independent predictors for developing an ICD. PD patients with pathological gambling were distinguished from PD with ICDs not otherwise specified and from PD controls of a younger age \[[@CR82]\].

#### Other Sociodemographic Characteristics {#Sec24}

According to Weintraub et al. \[[@CR84]\], PD patients with ICDs were most likely unmarried and living in the USA.

### Co-Morbidities {#Sec25}

#### Psychiatric Symptoms {#Sec26}

Mental illness was found to be significantly correlated to the presence of an ICD \[[@CR120]\], except in one study \[[@CR87]\]. Depression and anxiety were the highest-ranking correlates. A history of depression \[[@CR99]\], symptoms of depression \[[@CR85], [@CR121]\], and a higher score of depression \[[@CR66], [@CR80], [@CR82], [@CR95], [@CR122]\] were found to be predictors of the development of an ICD in patients with PD or RLS \[[@CR123]\]. In a longitudinal study, Joutsa et al. \[[@CR100]\] showed that the development of a novel ICD was associated with the concurrent increase in depression score. Conversely, one study reported only discrete symptoms of disinhibition \[[@CR85]\]. A history of anxiety \[[@CR99]\], trait anxiety \[[@CR94]\], symptoms of anxiety or stress \[[@CR123]\], and a higher anxiety score \[[@CR76], [@CR81], [@CR82], [@CR122]\] were also found to be predictors of the development of an ICD. Interestingly, a higher obsessive--compulsive score was reported in only one study \[[@CR122]\]. PD patients with pathological gambling were distinguished from PD with ICDs not otherwise specified and from PD controls with a higher severity of psychotic symptoms \[[@CR82]\].

#### Addictive Disorders {#Sec27}

In some studies, no link was found between addictive disorders and the development of an ICD \[[@CR68], [@CR87]\]. For others, substance use (and not a substance use disorder) of caffeine \[[@CR68], [@CR121]\], nicotine \[[@CR68], [@CR84], [@CR90]\], stimulants (tea, mate) \[[@CR96]\], alcohol \[[@CR88]\], or drugs \[[@CR70]\], as well as gambling practice \[[@CR120]\] was found to be associated with ICDs. A family history of pathological gambling was reported in two studies \[[@CR70], [@CR84]\].

#### Sleep Problems {#Sec28}

More sleep problems were reported in patients with RLS \[[@CR123]\] or PD \[[@CR82], [@CR96]\] with compulsions or ICDs.

#### Personality {#Sec29}

Predictably, the most assessed personality dimension was impulsivity, with authors reporting higher impulsivity scores \[[@CR94], [@CR122]\] and greater choice impulsivity \[[@CR122]\]. PD patients with ICDs also made errors in perceptual decision-making tasks. Clinically, this implies that PD patients with ICDs may make disadvantageous decisions as they are often 'in a rush' to decide \[[@CR113]\]. Similarly, a higher score of novelty-seeking \[[@CR81]\] was found to be associated with ICDs, especially among PD patients with compulsive sexual behavior \[[@CR122]\].

PD patients with ICDs were described as individuals with ineffective coping skills \[[@CR120]\], a higher level of neuroticism and lower levels of agreeableness and conscientiousness \[[@CR80]\], especially among PD patients with PG \[[@CR121]\] or compulsive sexual behaviors \[[@CR81]\]. EOPD patients with ICD symptoms scored higher on both self-assertive/antisocial and reserved/schizoid personality styles \[[@CR121]\]. For their part, PD patients with pathological gambling displayed higher scores of bizarre ideation and cynicism than those without pathological gambling or ICD \[[@CR124]\]. Finally, somatization appeared to be higher in patients with EOPD with ICD symptoms \[[@CR121]\].

### Biological Aspects {#Sec30}

*DRD3* p.Ser9Gly (rs6280) heterozygous variant CT genotype was found to be a predictor of ICDs among PD patients \[[@CR83]\]. Another genotyping study also indicated a significant association with tryptophan hydroxylase type 2 (TPH2) (recessive) and dopamine transporter (DAT) gene variants (dominant) in PD patients with ICD or dopamine dysregulation syndrome (DDS), all the more so when the severity of the ICD or DDS was high \[[@CR125]\]. TPH2 genotype was the strongest predictor of non-remission during follow-up. Finally, variants of *DRD1* rs4867798, *DRD1* rs4532, *DRD2*/*ANKK1* rs1800497, and *GRIN2B* rs7301328 were found to be associated with an increased risk of developing impulse control behaviors among PD patients \[[@CR126]\]. Kraemmer et al. \[[@CR127]\] found heritability of ICD behavior to be 57%, *OPRK1*, *HTR2A*, and *DDC* genotypes being the strongest genetic predictive factors.

An imaging study based on single photon emission computed tomography (SPECT) of the DAT concluded that the DAT density differed in PD patients with PG compared with PD patients without ICD or healthy controls. PD patients with PG showed a reduced tracer binding in the right ventral striatum, possibly reflecting either a reduction of mesolimbic projections or a lower membrane DAT expression on presynaptic terminals \[[@CR128]\]. A recent study suggested that changes in DAT availability over time increased the risk of incident ICDs \[[@CR129]\].

Another SPECT study showed a reduction of left putaminal and left inferior frontal gyrus tracer uptake in PD patients with ICDs compared with those without ICD \[[@CR130]\]. This frontostriatal dysconnectivity may be related to a DA and serotonin network dysfunction centered around the left putamen, supporting the idea of a monoaminergic frontostriatal disconnection syndrome as the biological basis of ICD symptoms in PD. This may reflect either a pre-existing neuronal trait vulnerability for impulsivity or the expression of a maladaptive synaptic plasticity under non-physiological dopaminergic stimulation \[[@CR130]\].

D~2~ receptor availability was no different between PD patients with or without ICDs at baseline, but a greater reduction of ventral striatum ^11^C-raclopride binding potential following [l]{.smallcaps}-dopa challenge with reward-related cue exposure relative to neutral cue exposure was observed \[[@CR131]\]. PD patients with pathological gambling seemed to have dysfunctional activation of DA autoreceptors in the midbrain and low DA tone in the anterior cingulate \[[@CR132]\]. A recent study failed to demonstrate any D~3~ upregulation in PD patients with ICD \[[@CR133]\].

Finally, an imaging study showed that PD patients with ICD, compared with those without ICD and healthy controls, had a thicker cortex in the anterior cingulate and the orbitofrontal cortex, which are cortical areas linked to impulsivity and inhibition behaviors \[[@CR134]\]. These structural abnormalities were correlated with the severity of the ICD.

Disease-Related Factors {#Sec31}
-----------------------

A summary of the results relating to disease-related factors is presented in Table [4](#Tab4){ref-type="table"} in Appendix.

### Age of Onset {#Sec32}

Most studies concluded that a younger age at PD onset was an independent predictor for developing an ICD in PD patients \[[@CR76]--[@CR78], [@CR80], [@CR82], [@CR94], [@CR99], [@CR102], [@CR105], [@CR106], [@CR118], [@CR135]\]---especially when the ICD was pathological gambling \[[@CR82]\]---or in RLS patients \[[@CR70]\]. Recently, Krishnamoorthy et al. \[[@CR83]\] emphasized a limit of 50 years and under in PD patients with ICDs.

### Disease Duration {#Sec33}

Similarly, a longer PD duration was found to be a factor \[[@CR80], [@CR82], [@CR102], [@CR137]\], except in a few cases \[[@CR68], [@CR85]\]. Rana et al. \[[@CR78]\] identified stages 1--2 of PD as one of the five common variables among patients who developed ICDs.

### Type of Disease {#Sec34}

Compared with PD patients without ICDs, those with ICDs displayed a higher frequency of motor complications \[[@CR68], [@CR80], [@CR102]\], with greater motor disease complexity \[[@CR76]\] and motor fluctuations \[[@CR93]\]. Conversely, PD patients with motor complications were more likely to have an ICD \[[@CR75]\]. Furthermore, a higher score on the Movement Disorder Society--Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part 1 was found in two studies \[[@CR93], [@CR94]\], as well as increased functional impairment, decreased motivation \[[@CR122]\] and a higher Mini-Mental State Examination (MMSE) score \[[@CR68]\]. Finally, patients with right-onset PD exhibited significantly higher levels of novelty-seeking than the patients with left-onset PD, which may increase the risk of developing an ICD when associated with the simultaneous use of DAAs \[[@CR138]\]. However, Pontone et al. \[[@CR85]\] and later Kenangil et al. \[[@CR101]\] found no significant association between PD features and the presence of ICD, and Ramirez Gómez et al. \[[@CR96]\] found a negative association between motor fluctuations or dyskinesias and ICDs.

### Biological Aspects {#Sec35}

To disentangle the effects of the disease process and DA medication and the development of ICDs, Al-Khaled et al. \[[@CR139]\] compared medicated and unmedicated PD patients, RLS patients and healthy controls. Using a delay discounting task, they demonstrated that unmedicated PD patients had a higher discounting rate. Thus, impulsive decision-making in PD patients may not be a side effect of dopaminergic treatment but rather a trait marker of PD. These results were in accordance with those of Aarts et al. \[[@CR140]\], who demonstrated the aberrant impact of rewards in PD, a reflection of reward-related impulsivity, was directly related to the degree of dopamine neuron loss, i.e., to a factor intrinsically related to the disease pathology itself.

Discussion {#Sec36}
==========

Main Findings {#Sec37}
-------------

Through our review, we have shown that this topic has been extensively studied over the last 10 years, allowing for us to obtain prevalence results from large samples. Publications mostly focused on iatrogenic factors, and progressively extended to patient- and disease-related factors. All this illustrates the complexity of this type of adverse drug reaction and the need to consider ICDs as multifactorial disorders. As recently noted by Voon et al. \[[@CR141]\], ICDs reflect the interactions of the DRT with an individual's susceptibility, and the underlying neurobiology of PD. The most robust findings, supported by several studies, include the type of DAA (having a higher selectivity for D~3~ receptors), dosage (higher daily dose), male gender (for PD), a younger age (although DAAs are more likely to be prescribed for younger PD patients), a history of depression and anxiety symptoms, an earlier onset of disease (it represents the same selection bias as for a younger age), a longer disease duration (for PD), and motor complications (for PD).

Limitations {#Sec38}
-----------

The value of the results, however, is limited by several aspects. Firstly, it is important to note that the assessment of ICDs was to a great extent heterogeneous, based on standardized clinical interviews, self-report questionnaires, medical records, and caregiver reports. Assessments were not always based on validated tools or consensual diagnostic criteria, with an explored period that was not always specified. Sometimes, the authors reported subclinical disorders, at other times only symptoms. On other occasions, they referred to lifetime or current disorders. This heterogeneity can be seen in the number of terms employed to describe ICDs: overeating, binge eating disorder, bulimia, compulsive shopping or buying, compulsive sexual behavior, hypersexuality, gambling, excessive gambling, problem gambling, pathological gambling, compulsive behavior, impulsive and compulsive behavior, impulse control disorder, ICD--not otherwise specified, impulsive control and repetitive behavior disorder, repetitive behavior disorder, etc. Although the inclusion of excessive behaviors among ICDs (for instance, overeating) may seem surprising, one must remembered that all display a high level of impulsivity. In this respect, they are in fact quite similar to disorders that are included in the other nosographic categories (i.e., 'Feeding and Eating Disorders' and 'Substance-related and Addictive Disorders'). The prevalence of ICDS in patients using DAAs varies widely according to which assessment tool is used. It should be noted that the true frequency may be underestimated due to patients' lack of insight into ICDs or their hesitation to acknowledge an ICD out of shame or embarrassment \[[@CR26]\].

Secondly, a large amount of heterogeneous data were collected on drugs, individuals, and underlying disease characteristics. However, the evaluation of certain factors, such as social determinants, was almost systematically neglected. Studies were not reproducible, making it difficult to draw general conclusions on the respective influence of each characteristic on the development of ICDs; this is especially true for psychological characteristics. Indeed, different studies evaluated different psychological dimensions, using different assessment tools. Poor decision-making and impulsivity are two dimensions regularly cited to influence ICD development. The challenge of differentiating between pre-existing personality traits, the impact of underlying disease, or the effects of DRT remains. A recent study demonstrated that exposure to pramipexole in PD patients without ICDs was associated with an increase in impulsive choices, acting essentially on decision-making processes \[[@CR142]\]. The authors speculated that, in PD patients without ICDs, pramipexole could modulate the top--down control, which is generally impaired in PD patients with ICDs. In healthy controls, pramipexole was shown to increase the activity of the NAcc, enhancing the interaction between the NAcc and the prefrontal cortex \[[@CR99]\]. It was suggested that pramipexole may exaggerate incentive and affective response to possible rewards, but reduce the top--down control of impulses. Furthermore, increased impulsivity may not only be dependent on medication but also on neuroanatomical abnormalities intrinsic to PD, with gray matter atrophy in impulse-control regions \[[@CR143]\].

Thirdly, we lack information relative to the drug formulations used in all trials. Indeed, extended-release (ER) forms of DAAs were progressively introduced, and several randomized controlled trials have compared their safety with immediate-release (IR) forms in the past few years. For instance, according to the review by Fishman \[[@CR144]\], the prevalence of ICDs is similar in both the IR and the ER forms of pramipexole. However, according to Stocchi et al. \[[@CR145]\], the relative recent marketing of the new ER DAAs has not yet resulted in conclusive data on the incidence of ICDs during their use. Thus, transdermal ragotidine and ER pramipexole may have a safer profile than IR pramipexole and IR/ER ropinirole \[[@CR146]\]. ER forms provide a better stability of plasmatic drug concentrations. Pharmacokinetic factors (rate of onset, half-life) are thought to be a critical determinant of the reinforcing effects and abuse potential of a drug. Some authors consider ICDs as additive disorders, even if only gambling disorder has been included in the "Substance-Related and Addictive Disorders" chapter in DSM-5 \[[@CR12]\]. We may assume that pharmacokinetic parameters could be involved, at least partly, in the development of ICDs. This is consistent with the fact that more ICDs have been described with DAA than with [l]{.smallcaps}-dopa, which is a prodrug needing a biotransformation to become an agonist (corresponding to an ER-like form). It is hypothesized that the acute release of DA in the ventral striatum in relation to a pulsed therapy could underlie the development of ICDs \[[@CR108]\].

Fourthly, most of the studies were cross-sectional, which is not an optimal strategy for the observation of personality traits or psychiatric co-morbidities and for determining whether or not they are predisposing factors or rather a consequence of an adverse drug reaction or the underlying disease. Nevertheless, two studies conducted in drug-naïve PD patients compared with healthy controls concluded that PD itself did not seem to confer an increased risk of development of an ICD \[[@CR147], [@CR148]\].

Fifthly, some authors conducted multiple comparisons without applying corrections or using multivariate analysis and concluded several significant associations irrespective of the risk of the type I error.

Finally, the MeSH term "Dopamine Agonists" used for this review did not include partial DAA drugs that are also known to cause ICDs, such as aripiprazole \[[@CR9], [@CR149]\] and flupentixole \[[@CR150]\].

Recommendations {#Sec39}
---------------

Recommendations are based on two key principles: the prevention of ICDs and the treatment of ICDs when they occur. Several studies were recently published that provide guidelines for the management of ICDs in PD patients \[[@CR45], [@CR51], [@CR151]\]. Part of these recommendations could also be used to address RLS or prolactinoma.

### "Prevention is Better than Cure": How to Achieve 'P4 Medicine'? {#Sec40}

'P4 medicine' can be achieved by adhering to the following recommendations:By encouraging a more systematic comprehensive assessment of patients to help in identifying those who are at risk of developing an ICD, sustained by the concept of *predictive* medicine;By better adapting the treatment strategy (avoiding drugs that are the most selective of D~3~ receptors in patients who are at greatest risk), sustained by the concept of *personalized* medicine;By providing full and clear information on these potential adverse drug reactions to patients and by raising awareness of the risk among caregivers, to promote early detection and medical intervention, sustained by the concept of *participatory* medicine;By preferring the prescription of ER formulations that have proven to be non-inferior to the IR formulations, and are better tolerated, and by routinely monitoring the patients, sustained by the concept of *preventive* medicine.

### When an ICD Occurs, it is Not Too Late {#Sec41}

The priority is to stop or to control excessive behavior, with the objective of harm minimization. The first stage aims at optimizing the DA treatment by:Reducing the [l]{.smallcaps}-dopa equivalent daily dose or discontinuing the DAA \[[@CR104]\], but with the risk of motor function deterioration and the occurrence of DAA withdrawal syndrome;Switching from one DAA to another that is less selective of the D~3~ receptors \[[@CR3], [@CR27]\];Combining oral DAA at a lower dose with apomorphine \[[@CR27]\] or orally disintegrating selegiline, which is a selective inhibitor of the monoamine oxydase type B \[[@CR152]\].

The second stage is to propose non-pharmacological approaches, especially cognitive and behavioral therapy (CBT) focusing on ICD \[[@CR153]\]. This implies promoting links between neurologists and psychiatrists and tailoring CBT to the particular characteristics of these patients in order to decrease the risk of relapse and dropout during treatment \[[@CR153]\].

In the event of a negative outcome, the third stage involves less conventional treatment options:Bilateral subthalamic nucleus (STN) deep-brain stimulation (DBS): case reports have shown an improvement after DBS \[[@CR154]\], but a recent review provided inconsistent results \[[@CR155]\].Specific pharmacological treatment of ICDs: several molecules were tested in a (very) small number of PD patients with ICDs. Antiepileptic drugs, such as topiramate \[[@CR156]\], valproate \[[@CR157]\], or zonisamide \[[@CR158]\], and anti-craving drugs, such as naltrexone \[[@CR159]\], could be effective therapeutic options, whereas antidepressant drugs, such as serotonin reuptake inhibitors \[[@CR160]\], or atypical antipsychotics, such as quetiapine \[[@CR161]\] or risperidone \[[@CR6]\], were met with mixed results. Clozapine was tested with encouraging results in a few patients \[[@CR162]\], but one must keep in mind its serious adverse effects and consider risks versus benefits for patients on an individual level.

Conclusion and Future Directions {#Sec42}
================================

The prevalence of ICDs ranged from 2.6 to 34.8% in PD patients, and from 7.1 to 11.4% in RLS patients. There are insufficient data available on prolactinoma to draw a conclusion with respect to prevalence. This review suggests that DAA use is associated with an increased risk in the occurrence of ICDs, under the combined influence of various factors. The most robust findings include the type of DAA (having a higher selectivity for D~3~ receptors), dosage (higher daily dose), male gender (for PD), a younger age (although DAAs are more likely to be prescribed in younger PD patients), a history of depression and anxiety symptoms, an earlier onset of disease (this pertains to the same selection bias as younger PD patients), a longer disease duration (for PD), and motor complications (for PD). Recently, a new clinical--genetic prediction model that has reached high accuracy was proposed \[[@CR127]\]. Guidelines to help in the prevention of ICDs and in their treatment when required do exist. Thus, identifying who is at risk of developing an ICD is crucial. Progress is still to be made to improve the evaluation of individual patients, using validated and consensual assessment tools, and by also integrating social factors. Further longitudinal studies including patients who have not yet developed an ICD would be useful in determining premorbid risk factors. Conducting literature-based meta-analysis, although difficult to achieve due to the heterogeneity of the data collected, could provide insight into the relative importance of the associated factors. Finally, large samples are needed to better characterize subtypes of patients with co-morbid ICD because beyond the associated factors reported in our review, it appears that they do not constitute a homogeneous group. This clinical intuition is well-supported by empirical evidence suggesting different evolutions after reduction or discontinuation of the DAA alleged to have cause the ICD. For some patients, DAA reduction or discontinuation is sufficient to obtain complete resolution of the ICD, while for others it is necessary to associate other measures. In the first case, one can imagine that the development of an ICD is a 'real' adverse drug reaction, linked to a particular sensitivity to DAAs, and which may be reversible by reducing DDA dosage under a specific threshold for each patient. In the second case, there may also be an addictive vulnerability involving biological, psychological, and environmental factors. DAA use would then only act as a catalyst, with the ICD finally evolving on its own. In these cases, the ICD also requires specialized addiction care.

Appendix {#Sec100}
========

Table 1Prevalence surveyStudiesYearSample sizeParticipantsDisease (type, duration, age at onset)DA drug (molecule, dosage, duration)DesignObjectivesMain resultsPontone et al. \[[@CR85]\]2006100PD patients (PD + ICD: 9 patients)PD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset (years): 44.3 (±9) vs. 48.6 (±9)\
Mean duration (years): 4.6 (±62.2) vs. 6.2 (±5.5)Pramipexole, ropinirole, amantadine, entacapone, selegiline, [l]{.smallcaps}-dopa\
*PD* *+* *ICD vs. PD--ICD:*\
[l]{.smallcaps}-dopa dose = 627 (±281) vs. 520 (±450) mgCross-sectionalTo determine the frequency of ICDsPrevalence = 9% (*n* = 9)\
ICDs: gambling (4%) = sexuality (4%) \> spending (3%)Grosset et al. \[[@CR98]\]2006388PD patientsPDPramipexole, ropinirole, pergolide, [l]{.smallcaps}-dopa, amantadine, entacapone, selegiline, anticholinergic.Cross-sectionalTo determine the frequency of excessive gamblingPrevalence = 4.4% (*n* = 17)Weintraub et al. \[[@CR86]\]2006272PD patientsPDPramipexole, ropinirole, pergolide, [l]{.smallcaps}-dopa, amantadineCross-sectionalTo determine the frequency of ICDsPrevalence = 6.6% (at some point during the course of PD) and 4% (currently)\
ICDs: sexuality and gamblingVoon et al. \[[@CR10]\]2006297PD patients (PD + ICD: 30 patients, PD--ICD: 277 patients)PD\
*PD* *+* *PG vs. PD* *+* *HS vs. PD* *+* *CS vs. PD--ICD:*\
Mean age at onset (years): 49 (±7) vs. 46 (±8) vs. 36 (±6) vs. 58 (±9)[l]{.smallcaps}-Dopa, DAA, pramipexole, ropinirole.Cross-sectional\
Case-controlTo determine the frequency of HS and CS*Prevalence:*\
HS: 2.4% (lifetime)/2.0% (current)\
CS: 0.7% (current)Driver-Dunckley et al. \[[@CR71]\]20079977 patients under DRT (current or past)Idiopathic RLS\
Mean duration: 24 years (±18)Pramipexole, ropinirole, pergolide, [l]{.smallcaps}-dopa, bromocriptineCross-sectionalTo determine the frequency of gambling or other abnormal behaviorsPrevalence = 11.4% (8 patients out of 70 who completed the questionnaire)\
Change in gambling (7%) and in sexual desire (5%) after the use of DRTGiladi et al. \[[@CR105]\]2007383193 PD patients (PD + ICD: 27 patients; PD -- ICD: 166 patients)\
190 age- and gender-matched HCPD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset (years): 51.5 (±12.2) vs. 58.7 (±12.1)\
Mean duration (years): 10.3 (±4.9) vs. 9.7 (±6.6)Ropinirole, pergolide, cabergoline, apomorphine, amandatine, selegiline, entacaponeCross-sectionalTo determine the frequency of ICDsPrevalence = 14% (*n* = 27)\
ICDs: sexuality (8.8%) \> eating (3.6%) \> gambling (3.1%) = shopping (3.1%)Crockford et al. \[[@CR87]\]2008140No demented-patients, with moderate to severe PDPDPramipexole, ropinirole, pergolide, bromocriptine, [l]{.smallcaps}-dopa\
LEDD = 707 (±402) mgCross-sectionalTo assess the prevalence of problem and PGPrevalence = 9.3% (vs. 1.3% in general population)Fan et al. \[[@CR88]\]2009444312 PD patients (PD + ICD: 11 patients; PD--ICD: 301 patients)\
132 controls (spouses/caregivers of the patients)PD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset (years): 58.7 (±6.7) vs. 60.1 (±10.6)\
Mean duration (years): 5.3 (±2.5) vs. 5.7 (±2.9)[l]{.smallcaps}-Dopa, piribedil, pramipexole, amantadine, pergolide, ergocriptine, bromocriptine\
*PD* *+* *ICD vs. PD--ICD:*\
Total LEDD = 487 (±289) vs. 392 (±224) mgCross-sectionalTo determine the frequency of ICDsPrevalence = 3.5% (*n* = 11, lifetime or current)Bostwick et al. \[[@CR65]\]2009267PD regional patients (to reduce the referral bias)PDDAAs (24.7%), with only 14.2% in the therapeutic range\
Carbidopa/[l]{.smallcaps}-dopa (88.6%) without a DAARetrospective (medical records, excluding those in which the behavior predated the PD onset)To determine the frequency of compulsive gambling and HSPrevalence = 2.6% (*n* = 7), but 18.4% of patients taking a DAA at therapeutic doses\
All cases were taking a DAA (either pramipexole or ropinirole), at therapeutic doses, but no case was taking carbidopa/[l]{.smallcaps}-dopa or a DAA at subtherapeutic dosesPallanti et al. \[[@CR163]\]20102424 PD patients who underwent STN DBSPDSTN DBSCross-sectional\
Patient- and relative-completed surveyTo determine the frequency of pundingPrevalence = 20.8% (*n* = 5)Weintraub et al. \[[@CR84]\]20103090PDDAAs and/or [l]{.smallcaps}-dopa (*n* = 3031)\
*DAAs (mean daily dosage and LEDDs):*\
Pramipexole: 3.1 mg (SD = 1.7) and 306.9 mg (SD = 168.2);\
Ropinirole: 11.1 mg (SD = 6.6) and 277.9 mg (SD = 164.9);\
Pergolide: 2.9 mg (SD = 1.7) and 286.6 mg (SD = 169.3)Cross-sectional\
Case-control (matching on age, sex and DAA treatment)\
*(DOMINION study)*To determine the frequency of ICDsPrevalence = 13.6% (3.9% with ≥ 2 ICDs)\
ICDs: shopping (5.7%) \> gambling (5%) \> eating (4.3%) \> sexuality (3.5%)Lee et al. \[[@CR102]\]20101167PG patientsPD\
Mean age at onset (years): 58 (±11)\
Mean duration (years): 7 (±4)Stable DRT for at least 3 months\
Mean duration of DRT: 5.0 years (± 3.8)Cross-sectionalTo determine the frequency of ICRBsPrevalence = 10.1%\
ICRBs: punding (4.2%) \> eating (3.4%) \> sexuality (2.8%) \> shopping (2.5%) \> gambling (1.3%)Kenangil et al. \[[@CR101]\]2010554PD patients (PD + ICD: 33 patients; PD -- ICD: 65 patients)PD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset (years): 49 (±9) vs. 52 (±11)\
Mean duration (years): 8 (±5) vs. 7 (±5)Pergolide, cabergoline, pramipexole, ropinirole, piribedil, lisuride\
*PD* *+* *ICD vs. PD-ICD:*\
DAA-LEDD = 369 (±181) vs. 319 (±208) mg\
Total LEDD = 702 (±2369) vs. 640 (±357) mgCross-sectionalTo determine the frequency of ICDsPrevalence = 5.9%\
ICDs: punding (57%) \> sexuality (42%) \> eating (27%) \> shopping (24%)Pourcher et al. \[[@CR123]\]20109797 RLS patients:\
32 untreated patients without compulsions\
53 DAA-treated patients without compulsions\
12 DAA-treated patients with compulsionsRLSStable DAA (average dose 0.52 mg pramipexole equivalent)Longitudinal\
T1: baseline\
T2: 4 months\
T3: 8 monthsTo determine the frequency of motor/behavioral compulsionsPrevalence = 12.4% (*n* = 12, development of a new compulsion)\
Compulsions: eating (*n* = 4) \> shopping (*n* = 3) \> trichotillomania = tic-like phenomena (*n* = 2) \> gambling (*n* = 1)Hassan et al. \[[@CR106]\]2011321DAAs-treated PD patientsPDRopinirole and pramipexole, [l]{.smallcaps}-dopa, selegiline, rasagiline, amantadine, entacaponeCohort (retrospective)To determine the frequency of compulsive behaviorsPrevalence = 16%\
Compulsive behaviors: gambling \> sexuality \> shopping \> eating \> hobbying \> computer useMartinkova et al. \[[@CR73]\]20112020 patients with pituitary adenomas (mostly prolactinomas) taking DAAsPituitary adenomasCabergoline, bromocriptine, and quinagolideCross-sectionalTo determine the frequency of ICDsPrevalence = 2/20 patients\
ICDs: sexuality (*n* = 1) and gambling and eating (*n* = 1)Auyeung et al. \[[@CR136]\]2011213PD patients (PD + ICD: 198 patients; PD--ICD: 15 patients)PD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset: 45.7 (±5.6) vs. 59 (±10.8) years\
Mean duration: 13.5 (±5.6) vs. 8.9 (±4.8) yearsBromocriptine, ropinirole, pramipexole, rotigotine, [l]{.smallcaps}-dopa\
*PD* *+* *ICD vs. PD--ICD:*\
Dose of DAA-LEDD = 277 (±147) vs. 85 (±98) mg\
Total LEDD = 1215 (±635) vs. 634 (±330) mgCross-sectionalTo determine the frequency of ICDsPrevalence = 7%Zahodne et al. \[[@CR164]\]20119696 PD patients (PD + BED: 9 patients; PD--BED: 87 patients)PD\
*PD* *+* *BED vs. PD--BED:*\
Mean age at onset (years): 58 (±8) vs. 56 (±13)\
Mean duration (months): 124 (±57) vs. 120 (±109)DAA\
STN DBS surgeryCross-sectionalTo determine the frequency of ICDs, in particular BED and subthreshold BEDPrevalence of BED = 1% (8.3% for subthreshold BED)\
Other ICDs: gambling (17.8%) \> shopping (11.5%) \> hoarding (8.3%) \> sexuality (1%)Voon et al. \[[@CR70]\]2011140RLSDAAs (ropinirole 2--4.5 mg/day: *n* = 3; pramipexole 0.72--1.4 mg/day: *n* = 3; lisuride 2.5 mg/day: *n* = 1; cabergoline 3 mg/day: *n* = 1)\
[l]{.smallcaps}-dopa (100 mg/day: *n* = 3)Cross-sectionalTo determine the frequency of ICDsPrevalence = 7.1%\
RLS + ICD (*N* = 10):\
Medication: DAAs (*n* = 7) \> [l]{.smallcaps}-dopa (*n* = 2) \> DAA + [l]{.smallcaps}-dopa (*n* = 1)\
ICDs: eating (*n* = 6) \> shopping (*n* = 5) \> gambling or punding (*n* = 3) \> sexuality (*n* = 2)Lim et al. \[[@CR137]\]2011200PD patientsPDPiribedil, pramipexole, ropinirole, bromocriptine, amantadine\
Low dosages of DRTCross-sectionalTo determine the frequency of ICDs and subsyndromal ICBsPrevalence any ICD = 23.5%\
ICDs: eating (13.5%) \> sexuality (13.0%) \> shopping (6%) \> gambling (3.5%)\
Prevalence any ICB = 35%\
ICBs: punding or hobbyism (20%) \> compulsive medication use (4.5%)Limotai et al. \[[@CR77]\]20121040PD patients, excluding those who were never exposed to DAA (PD + ICD: 89 patients; PD--ICD: 951 patients)PD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset: 52 (±10) vs. 59.7 (±12) years\
Mean duration: 11.5 (±6.1) vs. 11.3 (±6.8) years*PD* *+* *ICD vs. PD--ICD:*\
LEDD = 971 (±663) vs. 672 (±512) mg\
DAA-LEDD = 292 (±184) vs. 142 (±176) mg\
Total LEDD = 1122 (±644) vs. 779 (±543) mgRetrospective (cohort)To determine the frequency of DAWS, DDS and ICDsPrevalence of ICDs = 8.6%Joutsa et al. \[[@CR66]\]2012575575 PD patientsPDDA--[l]{.smallcaps}-dopa\
MAO-B inhibitorCross-sectional\
Postal surveyTo determine the frequency of ICDsPrevalence = 34.8%\
ICDs: sexuality (22.8%) \> eating (11.8%) \> shopping (10.1%) \> gambling (8.8%)Lipford and Silbert \[[@CR165]\]20125050 RLS patientsRLSPramipexoleRetrospective (cohort)To determine the frequency of ICDsPrevalence = 10% (*n* = 5)\
ICDs: eating, sexuality, gambling, shoppingPerez-Lloret et al. \[[@CR103]\]2012255203 PD patients (PD + ICD: 52 patients; PD--ICD: 151 patients)\
52 post-stroke patientsPD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean duration: 9.4 (±0.7) vs. 8.8 (±0.5) yearsDAA, [l]{.smallcaps}-dopa, MAO-B inhibitors, entacapone, amantadine\
*PD* *+* *ICD vs. PD--ICD:*\
LEDD ≥1050 mg: 63% vs. 42%Cross-sectional\
Case-controlTo determine the frequency of ICDsPrevalence among PD patients = 25% (0% among controls)\
PD + ICD (*n* = 52):\
Eating (14%) \> sexuality (10%) \> shopping (6%) \> gambling (3%)Valença et al. \[[@CR90]\]2013364152 PD patients (PD + ICD: 28 patients; PD--ICD: 124 patients)\
212 healthy controlsPD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean duration: 7.4 (±4.2) vs. 7.2 (±5.5) yearsPramipexole, amantadine, selegiline, [l]{.smallcaps}-dopa\
*PD* *+* *ICD vs. PD--ICD:*\
Daily pramipexole dosage = 2.9 (±1.2) vs. 0.85 (±1.4) mg\
LEDD = 732 (±404) vs. 644 (±397) mgCross-sectional\
Case-controlTo determine the frequency of ICDsPrevalence = 18.4% (vs. 4.2% in HC)Rana et al. \[[@CR78]\]2013140140 PD patientsPDAmantadine, pramipexole, [l]{.smallcaps}-dopaRetrospective chart reviewTo determine the frequency of ICDsPrevalence = 5.7% (*n* = 8)Kim et al. \[[@CR119]\]2013297297 PD patientsPDStable DRT for at least 3 monthsCross-sectionalTo determine the frequency of ICRBs (ICDs, RB, and DDS)Prevalence of ICRBs = 15.5%\
Prevalence of ICDs = 11.8%\
ICDs: sexuality (7.1%) \> gambling = eating = shopping (1.3%)Kim et al. \[[@CR135]\]20138989 PD patients with bilateral STN DBS surgeryPDBilateral STN DBS surgeryLongitudinal\
T1: baseline\
T2: follow-up (12 months after surgery)To determine the frequency of ICRBs and severity of ICRB before and after bilateral STN DBSPrevalence = 22.5% (pre-surgery)/25.8% (post-surgery)\
Preoperative ICRBs (*n* = 20): resolved (*n* = 6); improved (*n* = 7); idem (*n* = 4); worsened (*n* = 3)\
Postoperative de novo ICRBs (*n* = 9)Bastiaens et al. \[[@CR68]\]201346PD patients without previous history of ICDs, who were taking a DAAPD\
*PD* *+* *ICD vs. PD--ICD (baseline):*\
Mean age at onset (years): 57 (±10) vs. 57 (±9)\
Mean duration (years): 4 (1--19) vs. 5 (0--14)\
Motor complications: 61% vs. 25%DAAs\
*PD* *+* *ICD vs. PD--ICD (follow up:*\
Peak DAA-LEDD \[mg (median)\] = 300 (75--450) vs. 165 (50--400)Longitudinal (4-year prospective cohort study)To determine the frequency of ICDsPrevalence = 39.1%\
18 cases of ICDs (eating \> sexuality \> shopping \> gambling)Bayard et al. \[[@CR72]\]201314989 RLS patients:\
39 RLS drug-free\
50 RLS with DAAs\
30 healthy controlsRLSRLS + DAA: pramipexole or ropiniroleCross-sectional\
Case-control\
Decision-making tasks\
PSG record for the RLS drug-free groupTo determine the frequency of ICDsPrevalence = drug-free RLS (current: 2.5%/lifetime: 10.2%) and RLS under DAA (current: 2%/lifetime: 6%)\
Only binge eatingPoletti et al. \[[@CR97]\]2013805805 PD patients\
593 cognitively preserved\
212 dementedPD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset (years): 57 (±12) vs. 66 (±11)\
Mean duration (years): 10 (±6) vs. 10 (±7)[l]{.smallcaps}-Dopa, DAAs, amantadine, rasagilineCross-sectionalTo determine the frequency of ICDsPrevalence = 39.1%\
Prevalence in cognitively preserved PD patients = 9.6%\
Prevalence in demented PD patients = 3.8%Bancos et al. \[[@CR74]\]2014147Group A (*n* = 77): prolactinomas and current/past DAA use\
Group B (*n* = 70): non-functioning pituitary adenoma and no history of DAA useProlactinomaCabergoline, bromocriptineCross-sectional\
Postal surveyTo determine the frequency of ICDsPrevalence = 24.7% (group A)/17.1% (group B)Callesen et al. \[[@CR80]\]2014490490 PD patientsPDLEDD:\
Total: 555.4 (392.2) mg\
DAA: 114.8 (141.9) mgCross-sectionalTo determine the frequency of ICDsPrevalence = 35.9% (lifetime)/14.9% (current)Rodríguez-Violante et al. \[[@CR93]\]2014450300 PD patients (PD + ICD: 77 patients; PD--ICD: 223 patients)\
150 healthy controls (including 25 patients)PD[l]{.smallcaps}-Dopa, DAAs (especially pramipexole), amantadine\
*PD* *+* *ICD vs. PD--ICD:*\
DA-LEDD (mg) = 147 (±123) vs. 97 (±125)\
LEDD (mg) = 638 (±449) vs. 561 (±417)Cross-sectional\
Case-controlTo determine the frequency of ICDsPrevalence = 10.6% (5.3% in HC)\
All HC had only one type of ICD, whereas 4.6% of the PD presented with \>1 ICDGarcia-Ruiz et al. \[[@CR92]\]2014233233 PD patientsPD\
Mean duration: 5.9 years ± 4.1Oral (*n* = 197):\
Pramipexole\
Ropinirole\
Transdermal (*n* = 36):\
RotigotineCross-sectionalTo determine the frequency of ICDsPrevalence = 39.1%Pontieri et al. \[[@CR82]\]2015155155 PD patients:\
21 PD with PG\
36 PD with ICD-NOS\
98 No-ICDPD\
*PD* *+* *PG vs. PD* *+* *ICD-NOS vs. PD--ICD:*\
Mean age at onset (years): 51 (±8) vs. 57 (±10) vs. 61 (±9)\
Mean duration (years): 8 (±5) vs. 7 (±4) vs. 5 (±3)*PD* *+* *PG vs. PD* *+* *ICD-NOS vs. PD--ICD:*\
DAA-LEDD (mg) = 307 (±275) vs. 316 (±374) vs. 166 (±197)\
LEDD (mg) = 487 (±625) vs. 388 (±278) vs. 251 (±279)\
Total LEDD (mg) = 794 (±603) vs. 704 (±509) vs. 416 (±303)Study cohortTo determine the frequency of ICDsPrevalence = 36.8% (13.5% for PG)Todorova et al. \[[@CR108]\]20156060 PD patients:\
41 receiving Apo infusion\
19 receiving intrajejunal [l]{.smallcaps}-dopa infusionPD\
*PD* *+* *Apo vs. PD* *+* *[l]{.smallcaps}* *-dopa:*\
Mean duration (years): 14 (±5) vs. 16 (±6)Apo, [l]{.smallcaps}-dopa\
*PD* *+* *Apo vs. PD* *+* *[l]{.smallcaps}* *-dopa:*\
Mean dose (mg) = 106 (±24) vs. 1990 (±807)\
Mean duration of infusion = 16 vs. 16 h/dayLongitudinal (3-year prospective cohort study)To determine the frequency of ICDsApo group (*n* = 41): 4 patients had pre-existing *ICDs (*1 resolved and 3 attenuated after infusion initiation), 7 patients developed a new ICD (3 resolved, 1 had to stop Apo)\
[l]{.smallcaps}-dopa group (*n* = 19): 8 patients had pre-existing ICDs (6 resolved and 2 persisted after [l]{.smallcaps}-dopa infusion initiation), no new ICDs were observedSáez-Francàs et al. \[[@CR94]\]2016115115 PD patients:\
27 PD + ICD\
88 PD--ICDPD\
*PD* *+* *ICD vs. PD-ICD:*\
Mean age at onset (years): 53.7 (±10) vs. 60.3 (±9)\
Mean duration (months): 74.8 (±49) vs. 46.3 (±42)DAA, [l]{.smallcaps}-dopa, MAO-B inhibitors, amantadine\
*PD* *+* *ICD vs. PD-ICD:*\
DA-EDD (mg) = 216 (±135) vs, 114 (±135)\
LEDD (mg) = 660 (±403) vs. 440 (±521)Cross-sectionalTo determine the frequency of ICDsPrevalence = 23.48%\
Men: sexuality and gambling\
Women: eating and shopping.Vela et al. \[[@CR95]\]201617487 EOPD patients\
87 age- and gender-matched healthy controlsPD\
Median disease duration: 5 yearsRasagiline (*n* = 48), [l]{.smallcaps}-dopa (*n* = 55)\
DAAs (*n* = 70): rotigotine, pramipexole, ropinirole, cabergoline Cross-sectional\
Case-controlTo determine the frequency of ICDsPrevalence = 58.3% (vs. 32.9% in HC)Gescheidt et al. \[[@CR121]\]20168749 EOPD\
38 age-matched healthy controlsPD\
Mean duration (years): 11 (3--27)[l]{.smallcaps}-Dopa, DAAs, amantadine, anticholinergics\
DAA-LEDD (mg) = 300 (105--480)\
LEDD (mg) = 798 (300--1750)\
Total LEDD (mg) = 894 256--2050)Cross-sectional\
Case-controlTo determine the frequency of ICD symptomsPrevalence of ICD symptoms = 26.5% (10.5% in HC)\
Prevalence of PG = 8.2% (vs. 0 in HC)\
Prevalence of HS = 10.2% (vs. 0 in HC)Patel et al. \[[@CR166]\]2017312312 PD patients who were taking DAAS:\
156 PD who developed at least 1 AE\
156 who did not developed any AEPD\
Mean duration (years): 8.5 (±6.2)Ropinirole, pramipexole, rotigotine\
DAA-LEDD (mg) = 194 (±117)\
Total LEDD (mg) = 770 (±430)Retrospective chart reviewTo determine the prevalence of DAWSPrevalence of ICDs = 10.3%\
DAWS was experienced in 28% of patients who had an ICD (*n* = 32)Smith et al. \[[@CR129]\]2016320PD untreated patients and having a DAT imaging deficit at baselinePD\
*Baseline characteristics*:\
Mean disease duration (months): 6.6*Follow-up characteristics*:\
[l]{.smallcaps}-dopa, DAAs, MAO-B inhibitors, amantadineLongitudinal (3-year prospective cohort study)To determine the incidence of ICD symptomsCumulative incidence = 8% (year 1), 18% (year 2), and 25% (year 3)\
Cumulative incidence rate increased annually in those on DRT and decrease in those not on DRTAntonini et al. \[[@CR107]\]2016786PD patients treated by rotigotine transdermal patchPD\
Mean duration (years): 5 (±6)Rotigotine\
Duration of exposure (months): 49 (±18)Post hoc analysis of 6 open-label extension studiesTo determine the incidence of ICDsPrevalence = 9% (63/71 having concomitant [l]{.smallcaps}-dopa treatment)\
Incidence was relatively low during the first 30 months and higher over the next 30 monthsKraemmer et al. \[[@CR127]\]2016276PD untreated patients, free of ICD at baselinePD\
*Baseline characteristics*:\
Mean disease duration (months): 6.3 (±6.3)86% of the patients started DRT during the follow-up\
40% of the patients initiated a DAALongitudinal (3-year prospective cohort study)\
Genetic studyTo determine the prevalence of ICD behavior during follow-upPrevalence = 19%Ramirez Gómez et al. \[[@CR96]\]2017255255 PD patients:\
70 with ICD\
185 No-ICDPD\
*PD* *+* *ICD vs. PD--ICD*:\
Median duration (years): 4 vs. 10DAAs (pramipexole, ropinirole, bromocriptine, piribedil, rotigotine)Cross-sectionalTo determine the prevalence of ICDsPrevalence = 27.4%*AE* adverse event, *Apo* apomorphine, *BED* binge eating disorder, *CS* compulsive shopping, *DA* dopamine, *DAA* dopamine agonist, *DAA-LEDD* dopamine agonist [l]{.smallcaps}-dopa equivalent daily dose,*DAT* dopamine transporter, *DAWS* dopamine agonist withdrawal syndrome, *DBS* deep-brain stimulation, *DDS* dopamine dysregulation syndrome, *DRT* dopamine replacement therapy, *EDD* equivalent daily dose, *EOPD* early-onset Parkinson's disease, *HC* healthy control, *HS* hypersexuality, *ICB* impulsive and compulsive behavior, *ICD* impulse control disorder, *ICD-NOS* impulse control disorder not otherwise specified, *ICRB* impulsive control and repetitive behavior disorders, *[l]{.smallcaps}* *-dopa* levodopa, *LEDD* levodopa equivalent daily dose, *MAO-B* monoamine oxidase B, *No-ICD* without impulse control disorder, *PD* Parkinson's disease, *PG* pathological gambling, *PSG* polysomnography, *RB* repetitive behavior disorder, *RLS* restless legs syndrome, *SD* standard deviation, *STN* subthalamic nucleus, + indicates with, − indicates without Table 2Drug-related factorsStudiesYearSample sizeParticipantsDisease (duration, type, age at onset)DA drug (molecule, dosage, duration)DesignObjectivesMain resultsPontone et al. \[[@CR85]\]2006100PD patients (PD + ICD: 9 patients)PD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset: 44.3 (±9) vs. 48.6 (±9) years\
Mean duration: 4.6 (±62.2) vs. 6.2 (±5.5) yearsPramipexole, ropinirole, amantadine, entacapone, selegiline, [l]{.smallcaps}-dopa\
*PD* *+* *ICD vs. PD--ICD:*\
[l]{.smallcaps}-dopa dose = 627 (±281) vs. 520 (±450) mgCross-sectionalTo determine the correlates of ICDsDAAs (as a class, concerning only pramipexole or ropinirole) use\
Significant association with pramipexole (and not with ropinirole)Weintraub et al. \[[@CR86]\]2006272PD patientsPDPramipexole, ropinirole, pergolide, [l]{.smallcaps}-dopa, amantadineCross-sectionalTo determine the correlates of ICDsDAA use\
No significant association with a specific DAA (ropinirole, pramipexole, or pergolide)\
Significant association with higher doses of DAAsGrosset et al. \[[@CR98]\]2006388PD patientsPDPramipexole, ropinirole, pergolide, [l]{.smallcaps}-dopa, amantadine, entacapone, selegiline, anticholinergicCross-sectionalTo determine the correlates of excessive gamblingHigher daily doses of pramipexoleGiladi et al. \[[@CR105]\]2007383193 PD patients (PD + ICD: 27 patients; PD--ICD: 166 patients)\
190 age- and gender-matched HCsPD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset (years): 51.5 (±12.2) vs. 58.7 (±12.1)\
Mean duration (years): 10.3 (±4.9) vs. 9.7 (±6.6)Ropinirole, pergolide, cabergoline, apomorphine, amandatine, selegiline, entacaponeCross-sectionalTo determine the correlates of ICDsLonger duration of treatment with DAAsCrockford et al. \[[@CR87]\]2008140Not demented patients, with moderate to severe PDPDPramipexole, ropinirole, pergolide, bromocriptine, [l]{.smallcaps}-dopa\
LEDD (mg) = 707 (±402)Cross-sectionalTo determine the correlates of problem gambling and PGDAA useAbler et al. \[[@CR109]\]200912Female RLS patientsRLS\
Mean duration (years): 4 (±2)Pramipexole, ropinirole, cabergoline\
DAA doses (mg pramipexole equivalent) = 0.5 (±0.2)Crossover ('on' and 'off' DAA medication)\
fMRI coupled with a gambling game taskTo investigate the underlying neurobiologyChange in the neural signaling of reward expectation (mesolimbic dopaminergic hyperactivation) with DAA medication, underlying a sensitization towards ICDsFan et al. \[[@CR88]\]2009444312 PD patients (PD + ICD: 11 patients; PD--ICD: 301 patients)\
132 controls (spouses/caregivers of the patients)PD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset (years): 59 (±7) vs. 60 (±11)\
Mean duration (years): 5 (±3) vs. 6 (±3)[l]{.smallcaps}-dopa, piribedil, pramipexole, amantadine, pergolide, ergocriptine, bromocriptine\
*PD* *+* *ICD vs. PD--ICD:*\
Total LEDD = 487 (±289) vs. 392 (±224) mgCross-sectionalTo determine the correlates of ICDsDAA usevan Eimeren et al. \[[@CR110]\]20098PD patientsPatients with early-stage PD\
Mean duration (years): 4 (±3)*Combination of*\
[l]{.smallcaps}-dopa dose (mg/day) = 594 (±290)\
*And*\
Pramipexole dose (mg/day) = 2.3 (±1.1)Crossover (off medication, after [l]{.smallcaps}-dopa and after an equivalent dose of pramipexole\
fMRI coupled with a probabilistic reward taskTo investigate the underlying neurobiologyWith pramipexole: tonic dopaminergic stimulation specifically diminished reward processing in the lateral OFC\
DAAs may abate negative reinforcement in feedback-based learning\
This finding is drug-specific (not observed after [l]{.smallcaps}-dopa)van Eimeren et al. \[[@CR111]\]20101414 PD patients:\
7 with DAA-induced PG\
7 without PG (matched for DRT, age and PD duration and severity)PD\
The 2 groups of patients were matched for PD duration and severityThe 2 groups of patients were matched for DRTCross-sectional\
Case-control\
PET scanning coupled with a card selection gameTo investigate the underlying neurobiologyIn PD + DAA-induced PG: significant DAA-induced reduction of neuronal activity in brain areas that are implicated in impulse control and response inhibition (lateral OFC, RCZ, amygdala, GPe).Kenangil et al. \[[@CR101]\]2010554PD patients (PD + ICD: 33 patients; PD--ICD: 65 patients)PD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset (years): 49 (±9) vs. 52 (±11)\
Mean duration (years): 8 (±5) vs. 7 (±5)Pergolide, cabergoline, pramipexole, ropinirole, piribedil, lisuride\
*PD* *+* *ICD vs. PD--ICD:*\
DAA-LEDD (mg) = 369 (±181) vs. 319 (±208)\
Total LEDD (mg) = 702 (±2369) vs. 640 (±357)Cross-sectionalTo determine the correlates of ICDsNo association between ICDs and doses of DAAsWeintraub et al. \[[@CR84]\]20103090*DOMINION study*PDDAAs and/or [l]{.smallcaps}-dopa (*n* = 3031)\
DAAs (mean daily dosage and LEDDs):\
Pramipexole: 3.1 (SD = 1.7) and 306.9 (SD = 168.2) mg\
Ropinirole: 11.1 (SD = 6.6) and 277.9 (SD = 164.9) mg\
Pergolide: 2.9 (SD = 1.7) and 286.6 (SD = 169.3) mgCross-sectional\
Case-control (matching on age, sex and DAA treatment)To determine the correlates of ICDsBoth DAAs and [l]{.smallcaps}-dopa use, with the OR nearly twice as high for DAAsLee et al. \[[@CR102]\]20101167PG patientsPD\
Mean age at onset (years): 58 (±11)\
Mean duration (years): 7 (±4)Stable DRT for at least 3 months\
Mean duration of DRT: 5.0 years (± 3.8)Cross-sectionalTo determine the correlates of ICRBs*Multivariate analysis*:\
DAAs: dose-response relationship with the compulsive shopping, gambling, and sexual behaviors\
[l]{.smallcaps}-dopa: dose--response relationship with pundingVoon et al. \[[@CR112]\]20104414 PD + ICD patients\
14 PD patients\
16 medication-free normal controlsPDDAAs ± [l]{.smallcaps}-dopa\
DAA-LEDD (mg) = 161.5 (SD = 43.5) for PD ± ICD and 155.5 (SD = 57.3) for PDCrossover with a within- and between-subjects design\
('on' and 'off' DAA medication)To investigate the underlying neurobiologyGroup × medication interaction effect: *DAA status* was associated with increased impulsive choice and shorter reaction time and decision conflict reaction time in PD + ICD but not in PD\
Higher rate of spatial working memory errors in PD + ICD\
Higher rate of visual hallucinations or illusions in PDPallanti et al. \[[@CR163]\]20102424 PD patients who underwent STN DBSPDSTN DBSCross-sectional\
Patient-and-relative-completed surveyTo investigate the underlying neurobiologyNon-punders: started bilateral STN DBS on average 1.96 years before the pundersSohtaoglu et al. \[[@CR104]\]20102222 PD patients with ICDsPD\
Mean age at onset (years): 47 (±9)\
Mean duration (years): 11 (±6)DAA (mg/day) = 3.7 (±1.7)\
[l]{.smallcaps}-dopa (mg/day) = 239 (±252)Longitudinal\
T1: ICDs diagnosis\
T2: follow-upTo evaluate the outcome of ICDsRecovery from compulsive behaviors after reducing dosage of DAAs for 16/22 patientsVoon et al. \[[@CR114]\]20114414 PD + ICD\
14 PD\
16 medication-free normal controlsPDDDAsCrossover with a within- and between-subjects design ('on' and 'off' DAA medication)\
fMRI coupled with a gamble risk-taking taskTo investigate the underlying neurobiologyPD + ICD made more risky choices at lower 'gamble risk' than PD\
DAAs in PD + ICS enhanced sensitivity to gamble risk with the opposite effect in PD. PD + ICS have an increased risk-taking bias compared to PD when there is only the prospect of gain, but not where there are both prospects of gain and loss\
DAAs may enhance an unconscious bias towards risk in susceptible individuals, underpinned by decreased coupling of neural evaluation and risk in the ventral striatum, orbitofrontal cortex and anterior cingulateVoon et al. \[[@CR70]\]2011140RLS ± ICDRLSDAAs (ropinirole 2--4.5 mg/day: *n* = 3; pramipexole 0.72--1.4 mg/day: *n* = 3; lisuride 2.5 mg/day: *n* = 1; cabergoline 3 mg/day: *n* = 1)\
[l]{.smallcaps}-dopa (100 mg/day: *n* = 3)Cross-sectionalTo determine the correlates of ICDsHigher DAAs dose (mean DAA dose as LEDD mg/day: 63.7 \[SD = 52.7\] vs. 26.7 \[SD = 26.4\])Hassan et al. \[[@CR106]\]2011321DAA-treated PD patientsPDRopinirole and pramipexole, [l]{.smallcaps}-dopa, selegiline, rasagiline, amantadine, entacaponeCohort (retrospective)To determine the correlates of ICDs*Univariate analysis*:\
Median duration of DAA use\
Therapeutic dose\
Target dose\
Concurrent [l]{.smallcaps}-dopa\
SurgeryAuyeung et al. \[[@CR136]\]2011213PD patients (PD + ICD: 198 patients; PD--ICD: 15 patients)PD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset (years): 46 (±6) vs. 59 (±11)\
Mean duration (years): 14 (±6) vs. 9 (±5)Bromocriptine, ropinirole, pramipexole, rotigotine, [l]{.smallcaps}-dopa\
*PD* *+* *ICD vs. PD--ICD:*\
DAA-LEDD (mg) = 277 (±147) vs. 85 (±98)\
Total LEDD (mg) = 1215 (±635) vs.634 (±330)Cross-sectionalTo determine the correlates of ICDsHigher dose of DAA exposureÁvila et al. \[[@CR167]\]201125PD patients who developed ICBsPD\
Mean duration (years): 4 (1--21)Pramipexole, ropinirole, pergolide, cabergoline, rotigotine\
T1: 18/25 were taking DAA\
DAA-LEDD (mg) = 286 (±118)Longitudinal\
T1: ICBs diagnosis\
T2: follow-upTo analyze the long-term outcomes in relation to changes in DRT and psychiatric therapySignificant association between DRT and ICD, but not with punding\
Full or partial remission of the ICDs symptoms in 5 patients who did not reduce DRTZahodne et al. \[[@CR164]\]20119696 PD patients (PD + BED: 9 patients; PD--BED: 87 patients)PD\
*PD* *+* *BED vs. PD--BED:*\
Mean age at onset (years): 58 (±8) vs. 56 (±13)\
Mean duration (months): 124 (±57) vs. 120 (±109)DAA\
STN DBS surgeryCross-sectionalTo determine the correlates of BED and subthreshold BEDHistory of DBS\
No significant association with DAAsClaassen et al. \[[@CR115]\]20114141 DAA-treated PD patients:\
22 with ICDs\
19 No-ICDsPDPramipexole, ropinirole, [l]{.smallcaps}-dopaCross-sectional\
Crossover with a within- and between-subjects design ('on' and 'off' DAA medication)\
Risk taskTo investigate the underlying neurobiologyDAAs increased risk-taking in PD patients with ICDs, but not for those without ICDs (no difference in 'off' state)---this effect is maintained with low doses of DA agonists\
Risk adjustment after negative outcomes was not influenced by DAA state, ICD status, or their interaction\
Importance of DAA doses in explaining risk behaviorLim et al. \[[@CR137]\]2011200PD patientsPDPiribedil, pramipexole, ropinirole, bromocriptine, amantadine\
Low dosages of DRTCross-sectionalTo determine the correlates of ICDs*Multivariate analysis*: No significant associationSolla et al. \[[@CR75]\]2011349349 PD patients:\
87 without MC\
262 with MCPD\
*PD* *+* *MC vs. PD--MC:*\
Mean age at onset (years): 62 (±10) vs. 63 (±10)\
Mean duration (years): 11 (±6) vs. 6 (±6)[l]{.smallcaps}-Dopa, DAAs\
*PD* *+* *MC vs. PD-MC:*\
DAA-LEDD (mg) = 73 (±106) vs. 64 (±79)\
Total LEDD (mg) = 606 (±324) vs. 411 (±238)Cross-sectionalTo determine the correlates of motor complicationsAll the patients with ICDs were taking significantly higher LEDD, with concomitant more frequent use of DAAs (with the exception of patients with compulsive shopping)Vallelunga et al. \[[@CR168]\]20118989 PD patients:\
48 No-ICD\
41 with ICDsPD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset (years): 53 (±10) vs. 57 (±11)\
Mean duration (years): 9 (±4) vs. 11 (±8)*PD* *+* *ICD vs. PD--ICD:*\
DAA use: 40/41 vs. 38/48\
DAA-LEDD (mg) = 168 (±114) vs. 124 (±114)Cross-sectional\
Case-control studyTo determine the correlates of ICDs*Univariate analysis*:\
No significant association with variants of DRD2 *Taq1A*, COMT and DAT1Shotbolt et al. \[[@CR117]\]20125050 PD patients with a pre-operative assessmentPDDBSLongitudinalTo discuss ICD/DDS and DBS pre-operative and post-operative relationships29 patients proceeded to surgery (including 4/8 patients who had ICDs and/or DDS)\
1 has shown recurrence after 18 months of being free from ICD. In the remaining 3, none has shown recurrence at follow-up ranging from 17 to 41 monthsPolitis et al. \[[@CR89]\]20122424 PD patients:\
12 with hypersexuality\
12 controlsPDCross-sectional\
Case-control study with a within- and between-subjects design ('on' and 'off' DA medication)\
fMRI coupled with exposure to sexual cuesTo investigate the underlying neurobiology*Univariate analysis*:\
PD + hypersexuality\
Significantly more DAAs and significantly less [l]{.smallcaps}-DOPA\
Decreases in activation during the presentation of sexual cues relative to rest when the patients were OFF medication, but not ON medication\
DA drugs may release inhibition within local neuronal circuits in the cerebral cortex that may contribute to compulsive sexual behaviorLeroi et al. \[[@CR76]\]20129999 PD patients:\
35 PD + ICD\
26 PD + apathy\
38 control PDPD57.6% were taking DRTCross-sectional\
Case-controlTo determine the correlates of ICDs and apathy*Univariate analysis*:\
PD + ICD vs. PD + apathy\
Higher LEDDPerez-Lloret et al. \[[@CR103]\]2012255203 PD patients (PD + ICD: 52 patients; PD--ICD: 151 patients)\
52 post-stroke patientsPD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean duration: 9.4 years (±0.7) vs. 8.8 (±0.5)DAA, [l]{.smallcaps}-dopa, MAO-B inhibitors, entacapone, amantadine\
*PD* *+* *ICD vs. PD--ICD:*\
LEDD ≥1050 mg: 63% vs. 42%Cross-sectional\
Case-controlTo determine the correlates of ICDsExposure to DAAs or MAO-B inhibitors, with a dose-response fashion (non-linear dose--response relationship between DAAs and frequency of ICD symptoms)Joutsa et al. \[[@CR100]\]2012270270 PD patients:\
135 no ICDs\
22 novel ICDs\
31 resolved ICDs\
82 stable ICDsPDDAAs, [l]{.smallcaps}-dopa\
MAO-B inhibitorLongitudinal\
T1: baseline\
T2: follow-up (15 months later)To determine the correlates of ICDs development and resolution*Resolution of ICDs*:\
Lower DAA dose at baseline\
*Development of a novel ICDs*:\
No significant association with DAAs dosesLimotai et al. \[[@CR77]\]20121040PD patients, excluding those who were never exposed to DAA (PD + ICD: 89 patients; PD--ICD: 951 patients)PD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset (years): 52 (±10) vs. 59.7 (±12)\
Mean duration (years): 11.5 (±6.1) vs. 11.3 (±6.8)*PD* *+* *ICD vs. PD--ICD:*\
LEDD = 971 (±663) vs. 672 (±512) mg\
DAA-LEDD = 292 (±184) vs. 142 (±176) mg\
Total LEDD = 1122 (±644) vs. 779 (±543) mgRetrospective (cohort)To determine the correlates of DAWS, DDS, and ICDs*Univariate analysis concerning ICDs*:\
Higher doses of DAA, [l]{.smallcaps}-dopa, and total dopaminergic medications\
More frequent DAWS and DDSRana et al. \[[@CR78]\]2013140140 PD patientsPDAmantadine, pramipexole, [l]{.smallcaps}-dopaRetrospective chart reviewTo determine the correlates of ICDs5 common variables among the patients who developed ICDs, including: maximum dose of the drug; DAA useValença et al. \[[@CR90]\]2013364152 PD patients (PD + ICD: 28 patients; PD--ICD: 124 patients)\
212 HCsPD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean duration: 7.4 (±4.2) vs. 7.2 (±5.5) yearsPramipexole, amantadine, selegiline, [l]{.smallcaps}-dopa\
*PD* *+* *ICD vs. PD--ICD:*\
Daily pramipexole dosage = 2.9 (±1.2) vs. 0.85 (±1.4) mg\
LEDD = 732 (±404) vs. 644 (±397) mgCross-sectional\
Case-controlTo determine the correlates of ICDsHigher dose of pramipexoleLeroi et al. \[[@CR79]\]201311090 PD patients:\
35 PD with ICD\
55 PD without ICD\
20 HCsPDStable DRT for at least 2 monthsCross-sectional\
Case-control study with a within- and between-subjects design\
('on' and 'off' DA medication)\
Stop and delay-discounting tasks\
Genotyping for a subset of PD patientsTo investigate the underlying neurobiology*Univariate analysis ICD vs. Non-ICD*:\
ICD were associated with more complications of therapy and higher LEDD\
PD + ICD/'on' medication: no impairment on cognitive flexibility; greater impulsive choice; no difference on the response inhibition\
PD + ICD/'off' medication: no difference in impulsive choiceKim et al. \[[@CR135]\]20138989 PD patients with bilateral STN DBS surgeryPDBilateral STN DBS surgeryLongitudinal\
T1: baseline\
T2: follow-up (12 months after surgery)To determine the effect of STN DBS on ICRB20/89 patients had ICRB in the preoperative period, which improved for 13 of them\
9 patients developed de novo ICRB after surgery\
No significant association between postoperative worsening or de novo ICRBs and LEDD levelsBastiaens et al. \[[@CR68]\]201346PD without previous history of ICDs, who were taking a DAAPD\
*PD* *+* *ICD vs. PD--ICD (baseline):*\
Mean age at onset (years): 57 (±10) vs. 57 (±9)\
Mean duration (years): 4 (1--19) vs. 5 (0--14)\
Motor complications: 61% vs. 25%DAAs\
*PD* *+* *ICD vs. PD--ICD (follow up):*\
Peak DAA-LEDD (mg, median) = 300 (75--450) vs. 165 (50--400)Longitudinal (4-year prospective cohort study)To determine the correlates of ICDsHigher peak DAA dose\
Non-significant results: DAA treatment duration, cumulative DAA exposure, type of molecule, concomitant [l]{.smallcaps}-dopa, [l]{.smallcaps}-dopa dosage, total LEDD, DRT durationBayard et al. \[[@CR72]\]201314989 RLS patients:\
39 RLS drug-free\
50 RLS with DAA\
30 HCsRLSRLS + DAA: pramipexole or ropiniroleCross-sectional\
Case-control\
Decision-making tasks\
PSG record for the RLS drug-free groupTo investigate the underlying neurobiology(1) ICDs, impulsivity, and addictive behaviors are relatively uncommon in patients with RLS, with no difference between drug-free and DAA-treated patients\
(2) Reduced decision-making performances in patients with RLS when the outcome probabilities are unknown, with no difference between drug-free and DAA-treated patientsSharp et al. \[[@CR169]\]20133618 PD patients\
18 age-matched HCsPD[l]{.smallcaps}-Dopa (LEDD : 631.15 mg/day) 1 h before the second decision-making taskCross-sectional\
Case-control\
Vancouver gambling taskTo investigate the underlying neurobiologyNo significant difference between PD patients (ON or OFF medication) and HC when evaluating gains\
OFF [l]{.smallcaps}-dopa: PD patients show risk-aversion for large losses\
ON [l]{.smallcaps}-dopa: PD patients have normal perception of magnitude and probability for both loss and gainPoletti et al. \[[@CR97]\]2013805805 PD patients\
593 cognitively preserved\
212 dementedPD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset (years): 57 (±12) vs. 66 (±11)\
Mean duration (years): 10 (±6) vs. 10 (±7)[l]{.smallcaps}-Dopa, DAAs, amantadine, rasagilineCross-sectionalTo determine the correlates of ICDsDAA use (no difference between pramipexole and ropinirole)\
[l]{.smallcaps}-dopa useCallesen et al. \[[@CR80]\]2014490490 PD patientsPDTotal-LEDD: 555.4 (392.2) mg\
DAA-LEDD: 114.8 (141.9) mgCross-sectionalTo determine the correlates of ICDsHigher total LEDD (no difference on DAA-LEDD)Moore et al. \[[@CR91]\]20142.7 million ADE reportsFDA ADE reporting system6 FDA-approved DAAs: pramipexole, ropinirole, cabergoline, bromocriptine, rotigotine, apomorphineRetrospective disproportionality analysis during the 10-year periodTo analyze serious ADR reports about ICDs1580 reports of ICDs (+ gambling): 710 for DAAs and 870 for other drugs\
The 6 DAAs had a strong signal, the strongest with pramipexole and ropinirole (preferential affinity for the dopamine D~3~ receptor).Sachdeva et al. \[[@CR81]\]20147373 PD patients:\
20 with CSB\
11 with ICD--CSB\
42 PD controlsPD\
*PD* *+* *CSB vs. PD* *+* *ICD vs. PD--ICD:*\
Mean duration (months): 96 (±48) vs. 72 (±72) vs. 72 (±66)*PD* *+* *CSB vs. PD* *+* *ICD vs. PD--ICD:*\
LEDD = 941 (±668) vs. 800 (±619) vs. 706 (±693) mgCross-sectional\
Case-controlTo determine the correlates of CSB*PD* *±* *CSB vs. PD controls*:\
Higher LEDDGarcia-Ruiz et al. \[[@CR92]\]2014233233 PD patientsPD\
Mean duration: 5.9 years ± 4.1*Oral (n* *=* *197)*:\
Pramipexole\
Ropinirole\
*Transdermal (n* *=* *36)*:\
RotigotineCross-sectionalTo determine the correlates of ICDsOral DAAs\
Rasagiline useDjamshidian et al. \[[@CR113]\]20146144 PD patients:\
17 PD + [l]{.smallcaps}-Dopa + DAA\
12 PD + [l]{.smallcaps}-Dopa only\
15 PD + ICDs\
17 HCsPDDAAs: pramipexole (*n* = 15), ropinirole (*n* = 9), rotigotine (*n* = 1) and apomorphine (*n* = 1)\
[l]{.smallcaps}-dopa (*n* = 12)Cross-sectional\
Case-control\
Perceptual inference and reaction time tasksTo investigate the underlying neurobiology*PD* *±* *ICD vs. HC*:\
Faster reaction times, presumably reflecting lower decision thresholds and poorer information sampling\
*PD with* *[l]{.smallcaps}* *-dopa* *±* *DAA vs. with* *[l]{.smallcaps}* *-Dopa only*:\
Faster reaction timesRodríguez-Violante et al. \[[@CR93]\]2014450300 PD patients (PD + ICD: 77 patients; PD--ICD: 223 patients)\
150 HCs (including 25 patients)PD[l]{.smallcaps}-Dopa, DAAs (especially pramipexole), amantadine\
*PD* *+* *ICD vs. PD--ICD:*\
DAA-LEDD (mg) = 147 (±123) vs. 97 (±125)\
LEDD (mg) = 638 (±449) vs. 561 (±417)Cross-sectional\
Case-controlTo determine the correlates of ICDsDAA use\
Higher DAA-LEDDOlley et al. \[[@CR120]\]20154040 PD patients:\
20 PG_PD\
20 NG_PDPD\
*PG_PD vs. NG_PD:*\
Mean age at onset (years): 56.4 (±9) vs. 59.4 (±8)\
Mean duration (years): 8 (±5) vs. 7.9 (±4)Cabergoline, pramipexole, pergolide, bromocriptine, [l]{.smallcaps}-dopaCross-sectional\
Case-controlTo explore the temporal relationships between problem gambling and DRT90% of PG_PD identified a noticeable increase in their gambling behaviors and urges after commencing DRT, within 3 or 6 months\
80% of PG_PD changed the dosage, class, or type of DRT, and within this group, 30% had ceased gambling and 50% had decreased gambling behaviorsClaassen et al. \[[@CR116]\]20153624 PD patients:\
12 PD + ICDs\
12 PD--ICD\
12 HCsPDAll patients were taking DAAs and about half were taking concomitant [l]{.smallcaps}-dopaCross-sectional\
Case-control study with a within- and between-subjects design ('on' and 'off' DAA)\
Stop-signal taskTo investigate the underlying neurobiologyNo significant difference on motor-impulsivity between PD-ICD and HC\
PD + ICDs stopped faster than both other groups, in both medication states ('on' and 'off' DAAs)\
There was an opposite effect on Go Reaction Time between patients with DAA monotherapy (DAA administration speeds Go Reaction Time) and those with [l]{.smallcaps}-dopa co-therapy (DAA administration slows Go Reaction Time)Pontieri et al. \[[@CR82]\]2015155155 PD patients:\
21 PD + PG\
36 PD + ICD-NOS\
98 No-ICDPD\
*PD* *+* *PG vs. PD* *+* *ICD-NOS vs. PD--ICD:*\
Mean age at onset (years): 51 (±8) vs. 57 (±10) vs. 61 (±9)\
Mean duration (years): 8 (±5) vs. 7 (±4) vs. 5 (±3)*PD* *+* *PG vs. PD* *+* *ICD-NOS vs. PD--ICD:*\
DAA-LEDD (mg) = 307 (±275) vs. 316 (±374) vs. 166 (±197)\
LEDD (mg) = 487 (±625) vs. 388 (±278) vs. 251 (±279)\
Total LEDD (mg) = 794 (±603) vs. 704 (±509) vs. 416 (±303)Study cohortTo determine the correlates of ICDsPD patients with PG and ICD-NOS vs. No-ICD: higher doses of DRTSáez-Francàs et al. \[[@CR94]\]2016115115 PD patients:\
27 PD + ICD\
88 PD--ICDPD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset (years): 53.7 (±10) vs. 60.3 (±9)\
Mean duration (months): 74.8 (±49) vs. 46.3 (±42)DAA, [l]{.smallcaps}-dopa, MAO-B inhibitors, amantadine\
*PD* *+* *ICD vs. PD--ICD:*\
DAA-LEDD (mg) = 216 (±135) vs. 114 (±135)\
LEDD (mg) = 660 (±403) vs. 440 (±521)Cross-sectionalTo determine the correlates of ICDsDAA useVela et al. \[[@CR95]\]201687 EOPD patients\
87 age- and gender-matched HCsPD\
Median disease duration: 5 yearsRasagiline (*n* = 48), [l]{.smallcaps}-dopa (*n* = 55)\
DAAs (*n* = 70): rotigotine, pramipexole, ropinirole, cabergoline Cross-sectional\
Case-controlTo determine the correlates of ICDsDAA useChang et al. \[[@CR170]\]20161515 PD patients treated with LCIGPDIntraduodenal LCIG infusion during 16 h/day for 6 months\
Stop DA agonists: oral [l]{.smallcaps}-dopa/carbidopa authorized for nocturnal 'off' symptomsLongitudinal\
T1: baseline\
T2: follow-up (6 months)\
T2: follow-up (12 months)\
Open-label studyTo assess the efficacy and ADE profile of LCIG for the treatment of advanced PD(1) *Efficacy*:\
66% had a reduction in total LEDD, improvement of the part III of the UPDRS (at 6 and 12 months), reduction of the daily 'off' period and increase of the daily 'on' period (at 6 and 12 months) and improvement of functioning and well-being (PDQ-39) (at 6 and 12 months)\
(2) *ADEs*:\
The most common ADEs were reversible peripheral neuropathy secondary to vitamin B12 ± B6 deficiency (40%), local tube problems (40%), and ICDs or DDS (27%)\
3 patients who had prior ICD with DAAs did not develop ICD or DDS with LCIG infusion\
LEDD increased in patients with ICD and decreased in patients without ICDKrishnamoorthy et al. \[[@CR83]\]2016455170 PD patients:\
70 with ICDs\
100 No-ICD\
285 HCsPD[l]{.smallcaps}-Dopa (81%)\
DAAs (pramipexole or ropinirole) (58%)Cross-sectional Case-controlTo determine the correlates of ICDsDDA use\
Higher LEDDGescheidt et al. \[[@CR121]\]20168749 EOPD\
38 age-matched HCsPD\
Mean duration (years): 11 (3--27)[l]{.smallcaps}-Dopa, DAAs, amantadine, anticholinergics\
DAA-LEDD (mg) = 300 (105--480)\
LEDD (mg) = 798 (300--1750)\
Total LEDD (mg) = 894 (256--2050)Cross-sectional\
Case-controlTo determine the correlates of ICD symptoms*Univariate analysis*:\
Higher frequency of PG in EOPD treated with DAAsRamirez Gómez et al. \[[@CR96]\]2017255255 PD patients:\
70 with ICD\
185 No-ICDPD\
*PD* *+* *ICD vs. PD-ICD:*\
Median duration (years): 4 vs. 10DAAs (pramipexole, ropinirole, bromocriptine, piribedil, rotigotine)Cross-sectionalTo determine the correlates of ICDsDAA use*ADE* adverse drug event, *ADR* adverse drug reaction, *BED* binge eating disorder, *CSB* compulsive sexual behavior, *COMT* catechol-*O*-methyltransferase, *DA* dopamine, *DAA* dopamine agonist, *DAA-LEDD* dopamine agonist [l]{.smallcaps}-dopa equivalent daily dose, *DAT* dopamine transporter, *DAWS* dopamine agonist withdrawal syndrome, *DBS* deep-brain stimulation, *DDS* dopamine dysregulation syndrome, *DRT* dopamine replacement therapy, *EOPD* early-onset Parkinson's disease, *FDA* Food and Drug Administration, *fMRI* functional magnetic resonance imaging, *GPe* external pallidum, *HC* healthy control, *ICB* impulsive and compulsive behavior, *ICD* impulse control disorder, *ICD-NOS* impulse control disorder not otherwise specified, *ICRB* impulsive control and repetitive behavior disorders, *LCIG* levodopa--carbidopa intestinal gel, [l]{.smallcaps}-dopa levodopa, *LEDD* levodopa equivalent daily dose, *MAO-B* monoamine oxidase B, *MC* motor complications, *NG_PD* Parkinson's disease without problem gambling, *No-ICD* without impulse control disorder, *OFC* orbitofrontal cortex, *PD* Parkinson's disease, *PDQ-39* 39-item Parkinson's Disease Questionnaire, *PET* positron emission tomography, *PG_PD* Parkinson's disease with problem gambling, *PG* pathological gambling, *PSG* polysomnography, *RCZ* rostral cingulated zone, *RLS* restless legs syndrome, *SD* standard deviation, *STN* subthalamic nucleus, *Total LEDD* LEDD+DAA-LEDD, *UPDRS* Unified Parkinson's Disease Rating Scale, + indicates with, − indicates without Table 3Patient-related factorsStudiesYearSample sizeParticipantsDisease (type, duration, age at onset)DA drug (molecule, dosage, duration)DesignObjectivesMain resultsPontone et al. \[[@CR85]\]2006100PD patients (PD + ICD: 9 patients)PD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset: 44.3 (±9) vs. 48.6 (±9) years\
Mean duration: 4.6 (±62.2) vs. 6.2 (±5.5) yearsPramipexole, ropinirole, amantadine, entacapone, selegiline, [l]{.smallcaps}-dopa\
*PD* *+* *ICD vs. PD--ICD:*\
[l]{.smallcaps}-dopa dose = 627 (±281) vs. 520 (±450) mgCross-sectionalTo determine the correlates of ICDsDiscrete symptoms of depressed mood, irritability, appetite changes, and disinhibitionGiladi et al. \[[@CR105]\]2007383193 PD patients (PD + ICD: 27 patients; PD--ICD: 166 patients)\
190 age- and gender-matched HCsPD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset: 51.5 (±12.2) vs. 58.7 (±12.1) years\
Mean duration: 10.3 (±4.9) vs. 9.7 (±6.6) yearsRopinirole, pergolide, cabergoline, apomorphine, amandatine, selegiline, entacaponeCross-sectionalTo determine the correlates of ICDsMale genderCrockford et al. \[[@CR87]\]2008140Not demented patients, with moderate to severe PDPDPramipexole, ropinirole, pergolide, bromocriptine, [l]{.smallcaps}-dopa\
LEDD = 707 (±402) mgCross-sectionalTo determine the correlates of problem gambling and PGYounger age\
No significant association with psychiatric/SUD co-morbidityFan et al. \[[@CR88]\]2009444312 PD patients (PD + ICD: 11 patients; PD--ICD: 301 patients)\
132 controls (spouses/caregivers of the patients)PD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset: 58.7 (±6.7) vs. 60.1 (±10.6) years\
Mean duration: 5.3 (±2.5) vs. 5.7 (±2.9) years[l]{.smallcaps}-Dopa, piribedil, pramipexole, amantadine, pergolide, ergocriptine, bromocriptine\
*PD* *+* *ICD vs. PD--ICD:*\
Total LEDD (mg) = 487 (±289) vs. 392 (±224)Cross-sectionalTo determine the correlates of ICDsAlcohol daily useWeintraub et al. \[[@CR84]\]20103090*DOMINION study*PDDAAs and/or [l]{.smallcaps}-dopa (*n* = 3031)\
DAAs (mean daily dosage and LEDDs):\
Pramipexole 3.1 (±1.7) and 306.9 (±168.2) mg\
Ropinirole: 11.1 (±6.6) and 277.9 (± 164.9) mg\
Pergolide: 2.9 (±1.7) and 286.6 (±169.3) mgCross-sectional\
Case-control (matching on age, sex, and DAA treatment)To determine the correlates of ICDsLiving in the USA\
Younger age\
Being unmarried\
Current nicotine use\
Family history of gambling problemsCilia et al. \[[@CR128]\]20104329 PD patients:\
8 PD with PG\
21 PD--ICD (matched for demographic, clinical features, and mean daily DRT intake)\
14 HCsPD\
*PD* *+* *PG vs. PD--ICD:*\
Mean duration: 6 (±2) vs. 6 (±2) years[l]{.smallcaps}-Dopa + DAAs\
*PD* *+* *PG vs. PD--ICD:*\
Total LEDD (mg) = 831 (±294) vs. 852 (±301)\
DAA-LEDD (mg) = 241 (±118) vs. 252 (±121)Cross-sectional\
Case-control\
Imaging study (SPECT of DAT)To investigate the underlying neurobiologyDAT density differed between the 3 groups in both dorsal and ventral striata bilaterally\
Post hoc analysis: reduced tracer binding in the ventral striatum for PD with PG compared to PD without ICDLee et al. \[[@CR102]\]20101167PG patientsPD\
Mean age at onset: 58.3 (±10.5) years\
Mean duration: 6.6 (±4.3) yearsStable DRT for at least 3 months\
Mean duration of DRT: 5.0 years (±3.8)Cross-sectionalTo determine the correlates of ICRBsUnivariate analysis: male gender for gambling and sexualityPourcher et al. \[[@CR123]\]20109797 RLS patients:\
32 untreated patients without compulsions\
53 DAA-treated patients without compulsions\
12 DAA-treated patients with compulsionsRLSStable DAA (average dose 0.52 mg pramipexole equivalent)Longitudinal\
T1: baseline\
T2: 4 months\
T3: 8 monthsTo determine the correlates of motor/behavioral compulsionsMore stress, depression, and sleep problemsVoon et al. \[[@CR122]\]2011564564 PD patients:\
282 with ICDs\
282 No-ICD (matching on age, gender, and DAA treatment)PDDAAs ± [l]{.smallcaps}-dopaCross-sectional\
Case-control\
*(DOMINION study)*To determine the correlates of ICDsHigher depression, anxiety, and obsessive--compulsive symptoms scores\
Higher novelty-seeking and impulsivity scores\
Greater choice impulsivityVoon et al. \[[@CR70]\]2011140RLS ± ICDRLSDAAs (ropinirole 2--4.5 mg/day: *n* = 3; pramipexole 0.72--1.4 mg/day: *n* = 3; lisuride 2.5 mg/day: *n* = 1; cabergoline 3 mg/day: *n* = 1)\
[l]{.smallcaps}-dopa 100 mg/day: *n* = 3Cross-sectionalTo determine the correlates of ICDsFemale gender\
History of experimental drug use\
Family history of gambling disordersAuyeung et al. \[[@CR136]\]2011213PD patients (PD + ICD: 198 patients; PD--ICD: 15 patients)PD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset: 45.7 (±5.6) vs. 59 (±10.8) years\
Mean duration: 13.5 (±5.6) vs. 8.9 (±4.8) yearsBromocriptine, ropinirole, pramipexole, rotigotine, [l]{.smallcaps}-dopa\
*PD* *+* *ICD vs. PD--ICD:*\
DAA-LEDD = 277 (±147) vs. 85 (±98) mg\
Total LEDD = 1215 (±635) vs. 634 (±330) mgCross-sectionalTo determine the correlates of ICDsHistory of anxiety and depressionLim et al. \[[@CR137]\]2011200200 PD patientsPDPiribedil, pramipexole, ropinirole, bromocriptine, amantadine\
Low dosages of DRTCross-sectionalTo determine the correlates of ICDsMale genderVallelunga et al. \[[@CR168]\]20118989 PD patients:\
48 No-ICD\
41 with ICDsPD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset: 52.7 (±10.1) vs. 57.3 (±10.7) years\
Mean duration: 9 (±4.4) vs. 11.4 (±7.8) years*PD* *+* *ICD vs. PD--ICD:*\
DAA use: 40/41 vs. 38/48\
DAA-LEDD = 168 (±114) vs. 124 (±114) mgCross-sectional\
Case-control studyTo determine the correlates of ICDs*Univariate analysis*:\
Younger ageO'Sullivan et al. \[[@CR131]\]20111818 PD patients:\
7 No-ICD\
11 with ICDsPD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset: 45.1 (±11.2) vs. 47 (±8.8) years\
Mean duration: 11.9 (±11.3) vs. 10.7 (±6.4) years*PD* *+* *ICD vs. PD--ICD:*\
DAA-LEDD = 62 (±92) vs. 241 (±143) mg\
LEDD  = 636 (±325) vs. 708 (±319) mgCross-sectional\
Case-control study\
3 ^11^C-raclopride PET scansTo determine the correlates of ICDs*PD patients with ICDs vs. without*:\
No significant differences in baseline dopamine D~2~ receptor availability\
Greater reduction of ventral striatum ^11^C-raclopride binding potential following reward-related cue exposure, relative to neutral cue exposure, following [l]{.smallcaps}-dopa challengeLimotai et al. \[[@CR77]\]20121 040PD patients, excluding those who were never exposed to DAA (PD + ICD: 89 patients; PD--ICD: 951 patients)PD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset: 52 (±10) vs. 59.7 (±12) years\
Mean duration: 11.5 (±6.1) vs. 11.3 (±6.8) years*PD* *+* *ICD vs. PD--ICD:*\
LEDD = 971 (±663) vs. 672 (±512) mg\
DAA-LEDD = 292 (±184) vs. 142 (±176) mg\
Total LEDD = 1122 (±644) vs. 779 (±543) mgRetrospective (cohort)To determine the correlates of DAWS, DDS, and ICDs*Univariate analysis concerning ICDs*:\
Male gender\
Younger ageLeroi et al. \[[@CR76]\]20129999 PD patients:\
35 PD + ICD\
26 PD + apathy\
38 control PDPD57.6% were taking DRTCross-sectional\
Case-controlTo determine the correlates of ICDs and apathy*Univariate analysis*:\
PD + ICD vs. PD + apathy\
Higher level of anxiety.Joutsa et al. \[[@CR100]\]2012270270 PD patients:\
135 no ICD\
22 novel ICD\
31 resolved ICD\
82 stable ICDPDDAAs, [l]{.smallcaps}-dopa\
MAO-B inhibitorLongitudinal\
T1: baseline\
T2: follow-up (15 months later)To determine the correlates of ICDs*Resolution of ICD*:\
Female gender\
*Development of a novel ICD*:\
Concurrent increase in depression scoresJoutsa et al. \[[@CR66]\]2012575575 PD patientsPDDA--[l]{.smallcaps}-dopa\
MAO-B inhibitorCross-sectional\
Postal surveyTo determine the correlates of ICDsHigher depression score\
Male gender\
Age ≤65 yearsPerez-Lloret et al. \[[@CR103]\]2012255203 PD patients (PD + ICD: 52 patients; PD--ICD: 151 patients)\
52 post-stroke patientsPD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean duration: 9.4 (±0.7) vs. 8.8 (±0.5) yearsDAA, [l]{.smallcaps}-dopa, MAO-B inhibitors, entacapone, amantadine\
*PD* *+* *ICD vs. PD--ICD:*\
LEDD ≥1050 mg: 63% vs. 42%Cross-sectional\
Case-controlTo determine the correlates of ICDsAge \<68 yearsRay et al. \[[@CR132]\]20121414 PD patients:\
7 PD with PG\
7 PD without PGPDPatients withheld DRT for 12 h prior to the PET scans, and were given 1 mg of pramipexole 1 h prior to the scanCross-sectional\
PET coupled with gambling taskTo investigate the underlying neurobiologyPD patients with PG have dysfunctional activation of DA autoreceptors in the midbrain and low DA tone in the ACCShotbolt et al. \[[@CR117]\]20125050 PD patients with a pre-operative assessmentPDDBSLongitudinalTo discuss ICD/DDS and DBS pre-operative and post-operative relationships*Univariate analysis*:\
Patients with ICDs and/or DDS:\
Younger age\
Male genderRana et al. \[[@CR78]\]2013140140 PD patientsPDAmantadine, pramipexole, [l]{.smallcaps}-dopaRetrospective chart reviewTo determine the correlates of ICDs5 common variables among the patients who developed ICDs, including male genderValença et al. \[[@CR90]\]2013364152 PD patients (PD + ICD: 28 patients; PD--ICD: 124 patients)\
212 HCsPD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean duration: 7.4 (±4.2) vs. 7.2 (±5.5) yearsPramipexole, amantadine, selegiline, [l]{.smallcaps}-dopa\
*PD* *+* *ICD vs. PD--ICD:*\
Daily pramipexole dosage = 2.9 (±1.2) vs. 0.85 (±1.4) mg\
LEDD = 732 (±404) vs. 644 (±397) mgCross-sectional\
Case-controlTo determine the correlates of ICDsHistory of smokingKim et al. \[[@CR119]\]2013297297 PD patientsPDStable DRT for at least 3 monthsCross-sectionalTo determine the correlates of ICRBs (ICDs, RB and DDS)*ICDs*:\
Younger age\
Higher co-morbid RB and DDSBastiaens et al. \[[@CR68]\]201346PD without previous history of ICDs, who were taking a DAAPD\
*PD* *+* *ICD vs. PD--ICD (baseline):*\
Mean age at onset (years): 57 (±10) vs. 57 (±9)\
Mean duration (years): 4 (1--19) vs. 5 (0--14)\
Motor complications: 61% vs. 25%DAAs\
*PD* *+* *ICD vs. PD--ICD (follow-up):*\
Peak DAA-LEDD (mg, median) = 300 (75--450) vs. 165 (50--400)Longitudinal (4-year prospective cohort study)To determine the correlates of ICDsCigarette smoking\
Caffeine use\
Non-significant results: SUD, anxiety, or depression scoresKim et al. \[[@CR135]\]20138989 PD patients with bilateral STN DBS surgeryPDBilateral STN DBS surgeryLongitudinal\
T1: baseline\
T2: follow-up (12 months after surgery)To determine the effect of STN DBS on ICRBSeverity of ICRB worsened more after DBS in older patientsPoletti et al. \[[@CR97]\]2013805805 PD patients\
593 cognitively preserved\
212 dementedPD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset (years): 57 (±12) vs. 66 (±11)\
Mean duration (years): 10 (±6) vs. 10 (±7)[l]{.smallcaps}-Dopa, DAAs, amantadine, rasagilineCross-sectionalTo determine the correlates of ICDsMale gender\
Younger ageGarcia-Ruiz et al. \[[@CR92]\]2014233233 PD patientsPD\
Mean duration: 5.9 ± 4.1 years*Oral (n* *=* *197)*:\
Pramipexole\
Ropinirole\
*Transdermal (n* *=* *36)*:\
RotigotineCross-sectionalTo determine the correlates of ICDsYounger ageSachdeva et al. \[[@CR81]\]20147373 PD patients:\
20 with CSB\
11 with ICD with no CSB\
42 PD controlsPD\
*PD* *+* *CSB vs. PD* *+* *ICD vs. PD--ICD:*\
Mean duration (months): 96 (±48) vs. 72 (±72) vs. 72 (±66)*PD* *+* *CSB vs. PD* *+* *ICD vs. PD--ICD:*\
LEDD = 941 (±668) vs. 800 (±619) vs. 706 (±693) mgCross-sectional\
Case-controlTo determine the correlates of CSB*PD* *±* *CSB vs. PD controls*:\
Higher anxiety score\
*PD* *±* *CSB vs. PD* *±* *ICB and PD controls*:\
More open to new experiences (NEO--FFI)\
Less agreeable (NEO--FFI)Wu et al. \[[@CR171]\]20146829 PD + ICD + PIU\
19 PD\
20 HCsPD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset (years): 51.2 (±12) vs. 53.2 (±10)\
Mean duration (years): 12.4 (±8) vs. 10.4 (±6.2)*PD* *+* *ICD vs. PD--ICD:*\
DAA-LEDD = 349 (±307) vs. 537 (±329) mg\
LEDD  = 324 (±203) vs. 232 (±329) mg\
Total LEDD = 673 (±310) vs. 769 (±322) mgCross-sectionalTo explore Internet use in PD patients with and without ICDs*PD* *±* *ICD* *±* *PIU:*\
Higher score in the Y-BOCS-Internet questionnaireBancos et al. \[[@CR74]\]2014147Group A (*n* = 77): prolactinomas and current/past DAA use\
Group B (*n* = 70): non-functioning pituitary adenoma and no history of DAA useProlactinomaCabergoline, bromocriptineCross-sectional\
Postal surveyTo determine the correlates of ICDsOver-representation of males who developed an ICD in group A compared with group BCallesen et al. \[[@CR80]\]2014490490 PD patientsPDTotal LEDD: 555.4 (392.2) mg\
DAA LEDD: 114.8 (141.9) mgCross-sectionalTo determine the correlates of ICDsYounger age\
More symptoms of depression\
Higher level of neuroticism\
Lower levels of agreeableness and conscientiousnessPontieri et al. \[[@CR82]\]2015155155 PD patients:\
21 PD + PG\
36 PD + ICD-NOS\
98 No-ICDPD\
*PD* *+* *PG vs. PD* *+* *ICD-NOS vs. PD-ICD:*\
Mean age at onset (years): 51 (±8) vs. 57 (±10) vs. 61 (±9)\
Mean duration (years): 8 (±5) vs. 7 (±4) vs. 5 (±3)*PD* *+* *PG vs. PD* *+* *ICD-NOS vs. PD--ICD:*\
DAA-LEDD = 307 (±275) vs. 316 (±374) vs. 166 (±197) mg\
LEDD = 487 (±625) vs. 388 (±278) vs. 251 (±279) mg\
Total LEDD = 794 (±603) vs. 704 (±509) vs. 416 (±303) mgStudy cohortTo determine the correlates of ICDs*PD patients with PG and with ICD-NOS vs. No-ICD*:\
Higher severity of psychotic symptoms\
Higher 'sleep disturbances' and 'sexual preoccupation' scores\
*PD patients with PG vs. with ICD-NOS and No-ICD*:\
Younger age\
Higher severity of depressive and anxious symptoms\
*PD patients with ICD-NOS vs. No-ICD*:\
Younger ageOlley et al. \[[@CR120]\]20154040 PD patients:\
20 PG_PD\
20 NG_PDPD\
*PG_PD vs. NG_PD:*\
Mean age at onset (years): 56.4 (±9) vs. 59.4 (±8)\
Mean duration (years): 8 (±5) vs. 7.9 (±4)Cabergoline, pramipexole, pergolide, bromocriptine, [l]{.smallcaps}-dopaCross-sectional\
Case-controlTo explore the temporal relationships between problem gambling and DRTFactors influencing/contributing to changes in gambling:\
Periods of regular premorbid gambling\
Increased accessibility to gambling venues\
Ineffective coping skills\
Mental illnessTessitore et al. \[[@CR134]\]20155430 PD patients:\
15 PD with ICD\
15 PD--ICD (matched for age, sex, and educational level)\
24 age- and sex-matched HCsPD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean duration (years): 5.3 (±3) vs. 6.6 (±4)*PD* *+* *ICD vs. PD--ICD:*\
DAA-LEDD (mg) = 243 (±82) vs. 243 (±90)\
Total LEDD (mg) = 477 (±223) vs. 532 (±207)Cross-sectional\
Case-control\
Imaging study in 'on' phaseTo determine the correlates of ICDs*PD patients with ICD vs. without ICD and HC*:\
Thicker cortex in ACC and OFC\
Correlation between these structural abnormalities and ICDs severity (and not with cognitive deficits which characterized patients with ICD)Zainal Abidin et al. \[[@CR126]\]20159191 PD patients:\
52 with ICB\
39 without ICBPD\
*PD* *+* *ICB vs. PD--ICB:*\
Mean duration (years): 8 (±1) vs. 6 (±1)[l]{.smallcaps}-Dopa, DDAs\
DAA-LEDD (mg) = 83 (±12) vs. 1 (±0.2)\
LEDD (mg) = 346 (±42) vs. 173 (±27)Genetic studyTo investigate the association of selected polymorphism within the *DRD* and *GRIN2B* genes with the development of ICBVariants of *DRD1* rs4867798, *DRD1* rs4532, *DRD2*/*ANKK1* rs1800497, and *GRIN2B* rs7301328Payer et al. \[[@CR133]\]20155032 PD patients:\
11 PD + ICD\
21 PD--ICD\
18 age-, sex-, and education-matched HCsPD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean duration (years): 12 (±4) vs. 7 (±5)[l]{.smallcaps}-Dopa, DAAs (pramipexole, ropinirole, pergolide, amantadine, MAO inhibitors, COMT inhibitorsCross-sectional\
Case-control\
PET studyTo investigate the association between ICD in PD and D~3~ receptor availabilityD~3~ receptor levels were not elevated in PD with ICDSáez-Francàs et al. \[[@CR94]\]2016115115 PD patients:\
27 PD with ICD\
88 PD without ICDPD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset (years): 53.7 (±10) vs. 60.3 (±9)\
Mean duration (months): 74.8 (±49) vs. 46.3 (±42)DAA, [l]{.smallcaps}-dopa, MAO-B inhibitors, amantadine\
*PD* *+* *ICD vs. PD--ICD:*\
DAA--EDD = 216 (±135) vs. 114 (±135) mg\
LEDD = 660 (±403) vs. 440 (±521) mgCross-sectionalTo determine the correlates of ICDsHigher trait anxiety score\
Higher impulsivity scoresVela et al. \[[@CR95]\]201687 EOPD patients\
87 age- and gender-matched HCsPD\
Median disease duration: 5 yearsRasagiline (*n* = 48), [l]{.smallcaps}-dopa (*n* = 55)\
DAAs (*n* = 70): rotigotine, pramipexole, ropinirole, cabergoline Cross-sectional\
Case-controlTo determine the correlates of ICDsHigher depression scorePremi et al. \[[@CR130]\]20168484 PD patients:\
21 PD + ICD\
63 PD--ICDPD\
Mean duration: 1.7 ± 2.4 yearsRopinirole, pramipexole, rotigotine, amantadineCross-sectional\
Case-control\
SPECT imagingTo determine the correlates of ICDs*PD patients with ICD vs. No-ICD*:\
Reduction of left putaminal and left inferior frontal gyrus tracer uptake\
No functional covariance with contralateral basal ganglia and ipsilateral cingulate cortexCilia et al. \[[@CR125]\]2016442442 PD patients:\
154 PD + ICD/DDS\
288 PD--ICD/DDSPD\
*PD* *+* *ICD/DDS vs. PD--ICD/DDS:*\
Mean duration (years): 8.3 (±5.5) vs. 8.1 (±5.6)*PD* *+* *ICD/DDS vs. PD--ICD/DDS:*\
DAA-LEDD = 233 (±80) vs. 226 (±88) vs. 166 (±197) mg\
LEDD  = 475 (±291) vs. 456 (±282) mg\
Total LEDD = 707 (±301) vs. 689 (±302) mgCross-sectional\
Case-control\
Genotyping\
AND longitudinal:\
2- to 9-year prospective cohort for patients with ICD/DDS only (assessment at 1 year and at the last visit available)To determine the correlates of ICDs*PD patients with ICD/DDS vs. No-ICD/DDS:*\
Association with TPH2 (recessive) and dopamine transporter gene variants (dominant)\
Association between TPH2 genotype and severity of ICD/DDS\
*Follow-up*:\
Association between TPH2 genotype, premorbid depression and higher frequency of depressive symptoms AND more severe behavioral abnormalities, multiple ICDs, and a lower rate of full-remission\
TPH2 was the strongest predictor of no remission, while the extent of DA agonist daily dose reduction had no effectBrusa et al. \[[@CR124]\]20165858 PD patients:\
37 with PG\
21 without PG/ICDPDAny dopaminergic medicationCross-sectional\
Case-controlTo determine the correlates of PG*PD patients with PG vs. without PG/ICD*:\
Higher scores on the 3 MMPI-2 validity scales (lying, lying frequency, and defensive behavior)\
Higher scores on the 2 MMPI-2 content scales (bizarre ideation and cynicism)\
No significant difference for the clinical scalesKrishnamoorthy et al. \[[@CR83]\]2016425170 PD patients:\
70 with ICDs\
100 No-ICD\
285 HCsPD[l]{.smallcaps}-Dopa (81%)\
DAAs (pramipexole or ropinirole) (58%)Cross-sectional Case-controlTo determine the correlates of ICDs*DRD3* p.Ser9Gly (rs6280) heterozygous variant CTGescheidt et al. \[[@CR121]\]20168749 EOPD\
13 with ICD symptoms\
36 without ICD symptoms\
38 age-matched HCsPD\
Mean duration (years): 11 (3--27)[l]{.smallcaps}-Dopa, DAAs, amantadine, anticholinergics\
DAA-LEDD (mg) = 300 (105--480)\
LEDD (mg) = 798 (300--1750)\
Total LEDD (mg) = 894 (256--2050)Cross-sectional\
Case-controlTo determine the correlates of ICD symptoms*PD with ICD symptoms vs. without ICD symptoms (univariate analysis):*\
Anxiety\
Somatization\
Personality style: self-assertive/antisocial and reserved/schizoid\
Lower conscientiousness in EOPD patients with PGSmith et al. \[[@CR129]\]2016320Untreated PD patients with a DAT imaging deficit at baselinePD\
*Baseline characteristics*:\
Mean disease duration (months): 6.6*Follow-up characteristics*:\
[l]{.smallcaps}-dopa, DAAs, MAO-B inhibitors, amantadineLongitudinal (3-year prospective cohort study)\
DAT SPECT imaging (baseline and follow-up)To determine the correlates of ICD symptomsYounger age\
Lower DAT binding (i.e., greater decrease in DAT availability), ongoing loss over timeKraemmer et al. \[[@CR127]\]2016276PD untreated patients, free of ICD at baselinePD\
*Baseline characteristics*:\
Mean disease duration (months): 6.3 (±6.3)86% of the patients started DRT during the follow-up\
40% of the patients initiated a DAALongitudinal (3-year prospective cohort study)\
Genetic studyTo estimate ICD heritabilityHeritability = 57%\
The clinical--genetic prediction model reached highest accuracy\
*OPRK1*, *HTR2A*, and *DDC* genotypes were the strongest genetic predictive factorsRamirez Gómez et al. \[[@CR96]\]2017255255 PD patients:\
70 with ICD\
185 No-ICDPD\
*PD* *+* *ICD vs. PD--ICD:*\
Median duration (years): 4 vs. 10DAAs (pramipexole, ropinirole, bromocriptine, piribedil, rotigotine)Cross-sectionalTo determine the correlates of ICDsYounger age\
Stimulants use\
Rapid eye movement sleep disorder behavior*ACC* anterior cingulate, *CSB* compulsive sexual behavior, *COMT* catechol-*O*-methyltransferase, *DA* dopamine, *DAA-LEDD* dopamine agonist [l]{.smallcaps}-dopa equivalent daily dose, *DAA* dopamine agonist, *DAT* dopamine transporter, *DAWS* dopamine agonist withdrawal syndrome, *DBS* deep-brain stimulation, *DDS* dopamine dysregulation syndrome, *DRT* dopamine replacement therapy, *EOPD* early-onset Parkinson's disease, *HC* healthy control, *ICB* impulsive and compulsive behavior, *ICD* impulse control disorder, *ICD-NOS* impulse control disorder not otherwise specified, *ICRB* **i**mpulsive control and repetitive behavior disorders, *[l]{.smallcaps}* *-dopa* levodopa, *LEDD* levodopa equivalent daily dose, *MAO* monoamine oxidase, *MMPI-2* Minnesota Multiphasic Personality Inventory-2, *NEO-FFI* NEO Five-Factor Inventory, *NG_PD* Parkinson's disease without problem gambling, *No-ICD* without impulse control disorder, *OFC* orbitofrontal cortex, *PD* Parkinson's disease, *PET* positron emission tomography, *PG_PD* Parkinson's disease with problem gambling, *PIU* problematic Internet use, *PG* pathological gambling, *RB* repetitive behavior disorder, *RLS* restless legs syndrome, *SPECT* single photon emission computed tomography, *STN* subthalamic nucleus, *SUD* substance use disorder, *Total LEDD* LEDD+DAA-LEDD,*TPH2* tryptophan hydroxylase type 2, *Y-BOCS* Yale--Brown Obsessive Compulsive Scale, + indicates with, − indicates without, ± indicates with or without Table 4Disease-related factorsStudiesYearSample sizeParticipantsDisease (duration, type)DA drug (molecule, dosage, duration)DesignObjectivesMain resultsPontone et al. \[[@CR85]\]2006100PD patients (PD + ICD: 9 patients)PD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset: 44.3 (±9) vs. 48.6 (±9) years\
Mean duration: 4.6 (±62.2) vs. 6.2 (±5.5) yearsPramipexole, ropinirole, amantadine, entacapone, selegiline, [l]{.smallcaps}-dopa\
*PD* *+* *ICD vs. PD--ICD:*\
[l]{.smallcaps}-dopa dose = 627 (±281) vs. 520 (±450) mgCross-sectionalTo determine the correlates of ICDsNo significant association with PD features (age of onset, duration, stage, UPDRS score, [l]{.smallcaps}-dopa dose, etc.)Giladi et al. \[[@CR105]\]2007383193 PD patients (PD + ICD: 27 patients; PD--ICD: 166 patients)\
190 age- and gender-matched HCPD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset: 51.5 (±12.2) vs. 58.7 (±12.1) years\
Mean duration: 10.3 (±4.9) vs. 9.7 (±6.6) yearsRopinirole, pergolide, cabergoline, apomorphine, amandatine, selegiline, entacaponeCross-sectionalTo determine the correlates of ICDsYounger age at PD motor symptoms onsetKenangil et al. \[[@CR101]\]2010554PD patients (PD + ICD: 33 patients; PD--ICD: 65 patients)PD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset (years): 49 (±9) vs. 52 (±11)\
Mean duration (years): 8 (±5) vs. 7 (±5)Pergolide, cabergoline, pramipexole, ropinirole, piribedil, lisuride\
*PD* *+* *ICD vs. PD--ICD:*\
DAA-LEDD = 369 (±181) vs. 319 (±208) mg\
Total LEDD = 702 (±2369) vs. 640 (±357) mgCross-sectionalTo determine the correlates of ICDsNo significant association with severity of PD or presence of [l]{.smallcaps}-dopa-induced motor complicationsLee et al. \[[@CR102]\]20101167PG patientsPD\
Mean age at onset: 58.3 (± 10.5) years\
Mean duration: 6.6 (± 4.3) yearsStable DRT for at least 3 months\
Mean duration of DRT: 5.0 (± 3.8) yearsCross-sectionalTo determine the correlates of ICRBs*Univariate analysis*:\
Longer PD duration\
Younger age at PD onset\
Higher frequency of motor complicationsAuyeung et al. \[[@CR136]\]2011213PD patients (PD + ICD: 198 patients; PD--ICD: 15 patients)PD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset: 45.7 (±5.6) vs. 59 (±10.8) years\
Mean duration: 13.5 (±5.6) vs. 8.9 (±4.8) yearsBromocriptine, ropinirole, pramipexole, rotigotine, [l]{.smallcaps}-dopa\
*PD* *+* *ICD vs. PD--ICD:*\
DAA-LEDD = 277 (±147) vs. 85 (±98) mg\
Total LEDD = 1215 (±635) vs. 634 (±330) mgCross-sectionalTo determine the correlates of ICDsYounger age at PD onsetVoon et al. \[[@CR122]\]2011564564 PD patients:\
282 with ICDs\
282 No-ICD (matching on age, gender, and DAA treatment)PDDAAs ± [l]{.smallcaps}-dopaCross-sectional\
Case-control\
*(DOMINION study)*To determine the correlates of ICDsMore functional impairment\
Decreased motivationVoon et al. \[[@CR70]\]2011140RLS ± ICDRLSDAAs (ropinirole 2--4.5 mg/day: *n* = 3; pramipexole 0.72--1.4 mg/day: *n* = 3; lisuride 2.5 mg/day: *n* = 1; cabergoline 3 mg/day: *n* = 1)\
[l]{.smallcaps}-dopa (100 mg/d: *n* = 3)Cross-sectionalTo determine the correlates of ICDsYounger age at RLS onset (46.6 \[SD = 10.1\] vs. 57 \[15.9\] years)Hassan et al. \[[@CR106]\]2011321DAA-treated PD patientsPDRopinirole and pramipexole, [l]{.smallcaps}-dopa, selegiline, rasagiline, amantadine, entacaponeCohort (retrospective)To determine the correlates of ICDs*Univariate analysis*:\
Younger age at PD onset (51 vs. 59 years)Lim et al. \[[@CR137]\]2011200200 PD patientsPDPiribedil, pramipexole, ropinirole, bromocriptine, amantadine\
Low dosages of DRTCross-sectionalTo determine the correlates of ICDsLonger PD durationSolla et al. \[[@CR75]\]2011349349 PD patients:\
87 without MC\
262 with MCPD\
*PD* *+* *MC vs. PD--MC:*\
Mean age at onset (years): 62 (±10) vs. 63 (±10)\
Mean duration (years): 11 (±6) vs. 6 (±6)[l]{.smallcaps}-Dopa, DAAs\
*PD* *+* *MC vs. PD--MC:*\
DAA-LEDD (mg) = 73 (±106) vs. 64 (±79)\
Total LEDD (mg) = 606 (±324) vs. 411 (±238)Cross-sectionalTo determine the correlates of motor complicationsHigher frequency of ICDs in patients with MC (12.2%) than in patients without MC (3.4%)Vallelunga et al. \[[@CR168]\]20118989 PD patients:\
48 No-ICD\
41 with ICDsPD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset (years): 53 (±10) vs. 57 (±11)\
Mean duration (years): 9 (±4) vs. 11 (±8)*PD* *+* *ICD vs. PD--ICD:*\
DAA use: 40/41 vs. 38/48\
DAA-LEDD = 168 (±114) vs. 124 (±114) mgCross-sectional\
Case-controlTo determine the correlates of ICDs*Univariate analysis*:\
Younger age at PD onsetLimotai et al. \[[@CR77]\]20121 040PD patients, excluding those who were never exposed to DAA (PD + ICD: 89 patients; PD--ICD: 951 patients)PD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset (years): 52 (±10) vs. 60 (±12)\
Mean duration (years): 12 (±6) vs. 11 (±7)*PD* *+* *ICD vs. PD--ICD:*\
LEDD = 971 (±663) vs. 672 (±512) mg\
DAA-LEDD = 292 (±184) vs. 142 (±176) mg\
Total LEDD = 1122 (±644) vs. 779 (±543) mgRetrospective (cohort)To determine the correlates of DAWS, DDS, and ICDs*Univariate analysis concerning ICDs*:\
Younger age at PD onsetLeroi et al. \[[@CR76]\]20129999 PD patients:\
35 PD + ICD\
26 PD + apathy\
38 control PDPD57.6% were taking DRTCross-sectional\
Case-controlTo determine the correlates of ICDs and apathy*Univariate analysis*: PD + ICD vs. PD + apathy\
Younger age at PD onset\
Greater motor disease complexity.Aarts et al. \[[@CR140]\]20125832 PD patients:\
10 never-medicated\
22 after DA medication washout\
26 HCsPD\
Mean duration (years): 4 (±2)[l]{.smallcaps}-Dopa, DAAs, MAO-B inhibitorsCross-sectional with a within- and between-subjects design\
SPECT coupled with rewarded task-switching paradigmTo investigate the underlying neurobiologyRelation between aberrant reward processing and DA depletion in the striatum, but not long-term DA medication use\
Relation between the aberrant reward processing and the degree of DA cell lossBastiaens et al. \[[@CR68]\]201346PD without previous history of ICDs, who were taking a DAAPD\
*PD* *+* *ICD vs. PD--ICD (baseline):*\
Mean age at onset (years): 57 (±10) vs. 57 (±9)\
Mean duration (years): 4 (1--19) vs. 5 (0--14)\
Motor complications: 61 vs. 25%DAAs\
*PD* *+* *ICD vs. PD--ICD (follow-up):*\
Peak DAA-LEDD (mg, median) = 300 (75--450) vs. 165 (50--400)Longitudinal (4-year prospective cohort study)To determine the correlates of ICDsMotor complications\
Higher MMSE scores\
Non-significant results: PD durationRana et al. \[[@CR78]\]2013140140 PD patientsPDAmantadine, pramipexole, [l]{.smallcaps}-dopaRetrospective chart reviewTo determine the correlates of ICDs5 common variables among the patients who developed ICDs, including:\
Stage 1--2 of PD\
Young age at PD onsetKim et al. \[[@CR135]\]20138989 PD patients with bilateral STN DBS surgeryPDBilateral STN DBS surgeryLongitudinal\
T1: baseline\
T2: follow-up (12 months after surgery)To determine the effect of STN DBS on ICRBYounger age at PD onset was associated with a larger increase in MIDI scores in patients with ICRB (before or after surgery)Callesen et al. \[[@CR80]\]2014490490 PD patientsPDTotal LEDD: 555.4 (392.2) mg\
DAA LEDD: 114.8 (141.9) mgCross-sectionalTo determine the correlates of ICDsYounger age at PD onset\
Longer PD duration\
More motor symptomsRodríguez-Violante et al. \[[@CR93]\]2014450300 PD patients (PD + ICD: 77 patients; PD--ICD: 223 patients)\
150 HCs (including 25 patients)PD[l]{.smallcaps}-Dopa, DAAs (especially pramipexole), amantadine\
*PD* *+* *ICD vs. PD--ICD:*\
DAA-LEDD (mg) = 147 (±123) vs. 97 (±125)\
LEDD (mg) = 638 (±449) vs. 561 (±417)Cross-sectional\
Case-controlTo determine the correlates of ICDsMotor fluctuations\
Higher score on MDS-UPDRS part 1Harris et al. \[[@CR138]\]20158238 PD patients:\
19 right onset\
19 left onset\
44 HCsPD[l]{.smallcaps}-Dopa, DAAs, anticholinergic, COMT, MAO inhibitor\
*Right onset vs. left onset:*\
LEDD (mg) = 423 (±246) vs. 453 (±271)Cross-sectional\
Case-controlTo determine the correlates of side of onset of PD*Right-onset PD vs. left-onset PD*:\
Higher levels of novelty seekingAl-Khaled et al. \[[@CR139]\]20158337 PD (13 never-medicated and 24 medicated)\
24 RLS\
22 HCsPD and RLS\
*PD* *+* *medicated vs. PD--medicated vs. RLS:*\
Mean duration (years): 6 (±4) vs. 2 (±1) vs. 14 (±12)*PD* *+* *medicated vs. PD--medicated vs. RLS:*\
DAA-LEDD (mg) = 159 (±118) vs. 0 vs. 66 (±69)\
Total LEDD (mg) = 440 (±247) vs. 0 vs. 123 (±99)Cross-sectional with a between-subjects design\
Delay discounting taskTo investigate the underlying neurobiologyNever-medicated PD patients had a higher discounting rate than HCs and medicated RLS patients\
Impulsive decision-making in PD patients may not be a side effect of DA treatment, but rather a trait marker of PDPontieri et al. \[[@CR82]\]2015155155 PD patients:\
21 PD with PG\
36 PD with ICD-NOS\
98 No-ICDPD\
*PD* *+* *PG vs. PD* *+* *ICD-NOS vs. PD-ICD:*\
Mean age at onset (years): 51 (±8) vs. 57 (±10) vs. 61 (±9)\
Mean duration (years): 8 (±5) vs. 7 (±4) vs. 5 (±3)*PD* *+* *PG vs. PD* *+* *ICD-NOS vs. PD-ICD:*\
DAA-LEDD = 307 (±275) vs. 316 (±374) vs. 166 (±197) mg\
LEDD = 487 (±625) vs. 388 (±278) vs. 251 (±279) mg\
Total LEDD = 794 (±603) vs. 704 (±509) vs. 416 (±303) mgStudy cohortTo determine the correlates of ICDs*PD patients with PG and with ICD-NOS vs No-ICD*:\
Longer PD duration\
*PD patients with PG vs. with ICD-NOS and No-ICD*:\
Younger age at PD onset\
*PD patients with ICD-NOS vs. No-ICD*:\
Younger age at PD onsetSáez-Francàs et al. \[[@CR94]\]2016115115 PD patients:\
27 PD with ICD\
88 PD without ICDPD\
*PD* *+* *ICD vs. PD--ICD:*\
Mean age at onset (years): 53.7 (±10) vs. 60.3 (±9)\
Mean duration (months): 74.8 (±49) vs. 46.3 (±42)DAA, [l]{.smallcaps}-dopa, MAO-B inhibitors, amantadine\
*PD* *+* *ICD vs. PD--ICD:*\
DAA-LEDD = 216 (±135) vs. 114 (±135) mg\
LEDD = 660 (±403) vs. 440 (±521) mgCross-sectionalTo determine the correlates of ICDsYounger age at PD onset\
Higher score on the UPDRS-I subscaleKrishnamoorthy et al. \[[@CR83]\]2016455170 PD patients:\
70 with ICDs\
100 No-ICD\
285 HCsPD[l]{.smallcaps}-Dopa (81%)\
DAAs (pramipexole or ropinirole) (58%)Cross-sectional Case-controlTo determine the correlates of ICDsAge at PD onset \<50 yearsRamirez Gómez et al. \[[@CR96]\]2017255255 PD patients:\
70 with ICD\
185 No-ICDPD\
*PD* *+* *ICD vs. PD-ICD:*\
Median duration (years): 4 vs. 10DAAs (pramipexole, ropinirole, bromocriptine, piribedil, rotigotine)Cross-sectionalTo determine the correlates of ICDs*Negative association*:\
Presence of dyskinesias and motor fluctuations*COMT* catechol-*O*-methyltransferase, *DA* dopamine, *DAA-LEDD* dopamine agonist [l]{.smallcaps}-dopa equivalent daily dose,*DAA* dopamine agonist, *DAWS* dopamine agonist withdrawal syndrome; *DBS* deep-brain stimulation, *DDS* dopamine dysregulation syndrome, *DRT* dopamine replacement therapy, *HC* healthy control, *ICD* impulse control disorder, *ICD-NOS* impulse control disorder not otherwise specified, *ICRB* **i**mpulsive control and repetitive behavior disorders, *[l]{.smallcaps}* *-dopa* levodopa, *LEDD* levodopa equivalent daily dose, *MAO inhibitor* monoamine oxydase inhibitor,*MC* motor complications, *MDS-UPDRS* Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale, *MIDI* Minnesota Impulsive Disorders Interview, *MMSE* Mini-Mental State Examination, *No-ICD* without impulse control disorder, *PD* Parkinson's disease, *PG* pathological gambling, *RLS* restless legs syndrome, *SD* standard deviation, *SPECT* single photon emission computed tomography, *STN* subthalamic nucleus, *Total LEDD* LEDD+DAA-LEDD,*UPDRS* Unified Parkinson's Disease Rating Scale, + indicates with, − indicates without
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